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ABSTRACT 
 
Since their discovery, antibiotics have been a critical asset to medicine. They are 
responsible for saving lives and treating infections that could have been 
damaging or life-threatening in their absence. In short, we have become 
dependent on antibiotics. Now, however, antibiotic resistance in microbial 
infections has caused antibiotics, our “miracle drugs”, to diminish in their 
effectiveness.  This, in turn, has the potential to greatly impact the health of the 
entire human population.  Aspiring to become a doctor concerned with both the 
health of the general public and myself, I seek to understand this issue in its 
entirety and aim to produce a resource so that others can do the same. Through 
the use of scientific articles and other scholarly materials, I will examine, analyze, 
and compile research to determine what has caused antibiotic resistance, and 
what can be done to prevent it from worsening.  It is crucial that we understand 
the seriousness of this issue and the role it plays in our lives. By creating a 
resource that thoroughly explains the different aspects of antibiotic resistance, 
ranging from its origins and current antibiotic resistant infections to strategies 
that may help stop it, I hope to provide an opportunity for the general public to 
become aware and well-informed about this issue.   
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I. INTRODUCTION 
In the middle of the night a person awakens with a fever, by morning they 
feel worse, and by afternoon they are sitting in their doctor’s waiting room. Upon 
examination, the doctor makes note of certain symptoms that encourage her to 
run some tests. The results of those tests confirm her fears; the patient has a 
bacterial infection. The patient, however, isn’t worried; they hear about 
infections all the time as well as the antibiotics to treat them. Who really dies of a 
simple infection nowadays, anyway? The patient leaves the doctor, unhappy 
about the diagnosis, but confident that the prescribed antibiotic they now have 
will cure their ailment.  
 
A BRIEF HISTORY OF ANTIBIOITIC DISCOVERY  
It seems that in today’s society, antimicrobial agents have become 
commonplace, but our knowledge about these agents, especially antibiotics, is 
relatively recent. The road to understanding and employing antibiotics has been 
arduous, and the success over the years is the result of exhausting work and 
countless failures. People have been searching for methods to treat ailments for 
millennia. This quest goes back to rudimentary treatments ranging from mud, 
herbs, other plants and even magic. Although some ideas are more far-fetched 
than others, there have been remedies employed over the years that led to a 
greater understanding. Early people relied on plants to cure ailments and treat 
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wounds. An idea not entirely misguided considering that more than 2,500 plants 
contain antimicrobial properties [23]. Specific plants such as Hypericum 
perforatum, more commonly known as St. John’s Wort, and Symphytum officinal 
(a.k.a. Common Comfrey) also have actual antibacterial qualities [23]. In addition 
to making use of the local flora, other substances were discovered to be 
beneficial as treatments.  Mercury was successfully employed by the Egyptians as 
an antibacterial agent [23] and it was also thought that the red soils found in 
Jordan, Africa were capable of treating infections similar to our modern day 
antibiotics [2].  
These primitive treatment strategies were discovered during a time known 
as the pre-antibiotic era and were not only valuable for early cultures, but also 
served to introduce remedies that would later become useful in the antibiotic 
era. Jordan’s red soil, was one such example, which helped to lay the groundwork 
for scientific advancements and further understanding [2].  
As decades passed, and the wealth of knowledge increased, treatments 
grew more advanced and a search for new ones ensued. What came to be known 
as the aforementioned “Antibiotic Era,” began with the work of two individuals. 
The first was Paul Ehrlich, a German chemist who aimed to create a chemical 
compound that could leave healthy, body cells intact while eliminating bacteria. 
This chemical compound was often referred to as a “magic bullet” [2,19]. His 
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work targeted the bacterium, Treponema pallidum, which causes Syphilis, a 
sexually transmitted disease (STD). Along with a research team consisting of 
Alfred Bertheim and Sahachiro Hata, Ehrlich tested one compound after another 
on laboratory rabbits infected with the STD of interest [2]. Despite numerous 
failed attempts, they successfully discovered a chemical compound that could 
target the bacterium and leave the body’s cells unaffected. This 1909 discovery 
occurred after 605 failed chemical attempts and was justly coined “Compound 
606,” although it was officially named arsphenamine and was marketed under 
the trade name Salvarsan™ [2,19]. It became the main treatment for Syphilis and 
was the most prescribed drug on the market at that time [2].  
Arsphenamine dominated the pharmacy until the introduction of penicillin 
in the 1940s. What would come to be the first antibiotic began with a mere 
observation of mold. In 1928, Alexander Fleming examined a laboratory culture 
of Staphylcoccus bacteria and realized the growth of the bacteria was hindered 
by the presence of a mold containment [19]. The unexpected containment was 
Penicillium notatum. This moment of sheer chance spurred further investigation 
into the antibiotic properties associated with the mold. Fleming knew that the 
mold itself could be administered in a non-harmful form to living organisms, and 
coupled with the fact that it could inhibit bacterial growth, led Fleming to pursue 
a way to purify and stabilize the responsible compound. This task proved 
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challenging and unsuccessful for over a decade. However, in 1940 the answers 
had finally been revealed. A team of biochemists, Howard Walter Florey and 
Ernst Boris Chain, were able to purify penicillin and published their results [2,19]. 
Using their methods, it was possible to produce and clinically test penicillin. The 
mass production and successful human administration of penicillin would follow 
two years later.  
Both Paul Ehrlich and Alexander Fleming made noteworthy contributions 
to medicine and led the world into the antibiotic era. Although their overall drug 
discoveries are valuable, they also assisted future generations through the 
development of new laboratory strategies. Ehrlich’s work introduced both a 
treatment for Syphilis and a new protocol for drug research. The strategies he 
and his team employed during the research and development of arsphenamine 
created a framework that was eagerly adopted by pharmaceutical companies [2]. 
Following Ehrlich’s methods, countless new antimicrobial agents, along with 
other drugs, were created. Likewise, while making the observation that would 
lead to the development of penicillin, he also was unintentionally discovering a 
new method for testing the effectiveness of antibiotics and antibiotic-producing 
organisms [2]. Prior to Fleming, any testing of antimicrobials was accomplished 
only through the use of a large quantity of resources. However, observing the 
results of products on plates of pathogenic bacteria, as Fleming first had, was 
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more efficient and required fewer materials.  In this way, Ehrlich and Fleming 
provided valuable drug discoveries and changed the protocols employed in the 
laboratory.  As technology and knowledge have advanced since Ehrlich and 
Fleming’s contributions, additional antimicrobial compounds have been 
discovered or created. Nevertheless, the antibiotic industry was impacted by 
both the early uses of naturally occurring antimicrobials and the efforts of Ehrlich 
and Fleming.  
 
LABORATORY FINDINGS 
 
The bacterial domain is complex; there are not merely a handful of 
bacterial strains, but rather, multitudes to contend with. As described in the 
Literature Review below, bacteria can be categorized according to their shape. 
However, they can also be grouped based on cell wall chemical composition; 
three categories are typically recognized. Gram-positive bacteria have cells walls 
containing a thick portion of a sugar and amino acid polymer, peptidoglycan. 
Gram-negative bacteria also have peptidoglycan in their cell walls, but the layer is 
much thinner compared to their gram-positive relatives. This category of bacteria 
also contains an outer membrane called lipopolysaccharide (LPS) [49]. 
Additionally, the third category completely lack walls and are known as “cell wall-
deficient” (CWD). As the name suggest, these species of bacteria are unable to 
produce cell walls. [19]. 
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A common and valuable laboratory test called the Gram Stain is used to 
determine differences in cell wall composition. Developed by Hans Christian 
Gram in 1883, the Gram stain allows differentiation between gram-positive and 
gram-negative bacteria [19]. The procedure includes treatment with a crystal 
violet solution followed by an iodine solution that indicates the presence of 
gram-positive bacteria. The next steps are an alcohol rinse followed by a safranin 
counterstain to test for gram-negative bacteria [19]. If gram-positive bacteria are 
present, they will remain violet in color, while gram-negative bacteria will appear 
red. Distinguishing between gram-positive and negative bacteria is beneficial in 
identifying species of bacteria. 
Understanding cell wall differences of bacteria has contributed to the 
development of antibiotics, as well. Antibiotics can be classified as either broad 
or narrow spectrum. This differentiation in antibiotics refers to the types of 
bacteria certain types of antibiotics are effective against. Broad spectrum 
antibiotics are able to hinder both gram-positive and negative bacteria, while 
narrow spectrum antibiotics are only able to target one or the other [19].  
In an effort to better understand these differences, as well as gain 
firsthand experience in laboratory procedures and the efficacy of antibiotics, I 
examined the effects of four antibiotics on three bacterial species in a laboratory 
setting. The three species were Serratia marcescens, Micrococcus luteus, and 
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Citrobacter fruendii. S. marcescens [68] and C. fruendii [10,30] are gram-negative 
bacteria, while M. luteus is gram-positive [31]. These three species were each 
exposed to the same four drugs: penicillin, streptomycin, oxacillin, and 
sulfamethoxazole trimethoprim.  The first three are antibiotics, while the fourth 
is a synthetic, man-made drug. Streptomycin and sulfamethoxazole trimethoprim 
are both broad spectrum drugs [19,48]. Streptomycin is an aminoglycoside that 
damages bacteria by interfering with protein synthesis [19,77]. Sulfamethoxazole 
trimethoprim or “sulfa” is a member of the sulfonamide category of antibacterial 
agents. Penicillin and oxacillin are both narrow spectrum antibiotics. Penicillin is 
specifically a β-lactam antibiotic that disrupts cell wall synthesis in bacteria. 
Similar to penicillin, oxacillin falls into the β-lactam class of drugs and is closely 
related to methicillin [49,63].  
Based on the spectra of antibacterial drugs in conjunction with cell wall 
composition of the bacteria, the effects of each antibiotic can be predicted. Since 
streptomycin, and sulfa are broad-spectrum drugs, they potentially could inhibit 
growth of all three bacterial species. Oxacillin, as well, should have little effect on 
S. marcescens due to its similarity with penicillin. C. fruendii is commonly 
resistant to penicillin and oxacillin [10]. Nothing in literature suggested that M. 
luteus would be unresponsive to any of the four antibiotics. This information led 
me to predict that S. marcescens would only be inhibited by sulfa, M. luteus 
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should be affected by all four drugs, and C. fruendii should be responsive to 
streptomycin and sulfa.  
To test these predictions, 18 plates of nutrient agar were prepared. 
Nutrient agar is a non-selective medium that contains beef extract and allows 
many kinds of microbes to grow. The initial 18 plates were separated into three 
groups of six. Each group was double inoculated with one of the three bacterial 
species using a spreader. Common inoculation and sterilization procedures were 
implemented. Following preparation and inoculation, one antibiotic disk 
previously saturated with the specific antibacterial drug was applied to a “sector” 
of the plate. Each plate received a total of four antibiotic disks, one per sector for 
a total of four sectors (Fig. 1).  The plates were then incubated for 48 hours, after 
which, each zone of inhibition was measured. A zone of inhibition is an area 
immediately surrounding an antibacterial disk where no bacterial growth occurs.  
A zone of inhibition indicates the susceptibility of that microbe to the specific 
drug [49]. 
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Figure 1:    Drug disk setup on nutrient agar plates. The horizontal and vertical 
lines divide the plate into four “sectors.” Each sector contains one drug disk: 
streptomycin (SXT), oxacillin (OX), sulfa (S), and penicillin (P). 
 
Two additional plates were prepared to test for the presence of two gram-
positive bacteria often found on skin, Staphylococcus epidermidis and 
Staphylococcus aureus. Rather than the non-selective agar previously used, these 
bacteria were cultured on plates containing mannitol salt. Mannitol salt is 
selective because it normally inhibits gram-negative bacteria. Swab samples 
taken from inside my nostrils and between my toes were used to inoculate the 
plates. The plates were then incubated for 48 hours.  
The results of the antibacterial drug experiment aligned closely with the 
predictions previously stated. All zones of inhibition were measured to determine 
the efficacy of each antibiotic on each bacterial species. S. marcescens was only 
inhibited by sulfa and maintained an average 3 mm zone of inhibition for all six 
plates (Fig. 2). M. luteus was inhibited by all four antibiotics (Fig. 2). For this 
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particular bacterium, the average zone of inhibition for streptomycin was 7.5 
mm, oxacillin was 11 mm, sulfa was 5.8 mm, and penicillin was 18.7 mm. C. 
fruendii was affected by streptomycin and sulfa, but not by oxacillin or penicillin 
(Fig. 2). Streptomycin’s zone of inhibition was 8.8 mm and sulfa’s was 4.7 mm.  
The two mannitol salt plates showed growth of more than 300 colonies of S. 
epidermidis, but no S. aureus growth occurred. These results indicate that I 
harbor S. epidermidis colonies on my skin, but not S. aureus. 
 
PLATE 
# 
S. marcescens (mm) M. luteus (mm) C. fruendii (mm) 
SXT OX S P SXT OX S P SXT OX S P 
1 0 0 3 0 7 11 5 20 9 0 4 0 
2 0 0 3 0 9 11 5 18 9 0 6 0 
3 0 0 3 0 7 11 7 19 9 0 5 0 
4 0 0 3 0 7 10 6 18 8 0 5 0 
5 0 0 3 0 8 12 6 20 9 0 4 0 
6 0 0 3 0 7 11 6 17 9 0 4 0 
 
Figure 2:     Measurements, in millimeters, for the zones of inhibition observed on 
three sets of 6 agar plates inoculated with S. marcescens, M. luteus, and C. 
fruendii, respectively. Legend: streptomycin (SXT), oxacillin (OX), sulfa (S), and 
penicillin (P) disks.  
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The results of this study supported previous research as well as my 
hypotheses. While this study did not contribute to the discovery of any new 
information, it did serve as an important personal educational and informational 
lesson into the effects of antibacterial drugs on bacteria.  Understanding the 
different categories of bacteria based on cell wall differences, as well as being 
introduced to antibiotic spectra and laboratory procedures for bacterial 
identification and testing, provided me with a firm foundation to begin 
understanding the issue of antibiotic resistance.  
 
II. LITERATURE REVIEW 
 Antibiotic resistance is a term used in situations where an antibiotic, when 
applied to a microbe, will have either no, or a diminished effect on the microbe. 
The phrase, “antibiotic resistance,” is frequently used by, and has become very 
familiar to, today’s society. In order to truly understand antibiotic resistance, it is 
important to be aware of the history of antibiotics. In order to glean a greater 
understanding of this multi-faceted issue, scientific literature published prior to 
2000 has been examined. Throughout this collection of sources, reoccurring 
topics emerged that serve as the basis for developing a sound foundation about 
antibiotic resistance.  A majority of sources explained the mechanisms by which 
antibiotic resistance develops, whereas others focused on the uses of antibiotics 
and the impacts their existence has created. I consulted additional references by 
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Chee-Sanford, Aminov, Krapac, Garrigues-Jeanjean, and Mackie [9], Cohen and 
Tauxe [11], Falkiner [22], Greko [27], Kumar, Gupta, Chander, and Singh [35], 
McManus, Stockwell, Sundin and Jones [54], Mølbak et al. [55], Summers [79], 
van den Bogaard and Stobberingh [81], Voss, Loeffen, Bakker, Klaassen, and Wulf 
[83], and Wilkins [87]. I also read two articles by Levy [39,40] and two articles by 
Levy, FitsGerald, and Macone [42,43]. I consulted all of these references in order 
to develop a broader understanding of the issues surrounding antimicrobial 
resistance as I embarked on my research 
 The discovery and development of antibiotics allowed for large 
improvements to the health care system. Antibiotics, initially penicillin, increased 
the survival rates of patients by providing a means to counteract infections and 
they rapidly became a staple in healthcare. While enjoying the benefits of 
antibiotics, few knew to be concerned about the long-term effects associated 
with increasing antibiotic use. Even geneticists who specialized in bacteria 
dismissed any notions of concern by whole-heartedly believing that bacterial 
mutation rates were too low to allow for resistance to develop [14]. 
Unfortunately, there were grounds for concern. As antibiotic use persists, 
infections previously treated with certain antibiotics begin to no longer respond 
to the same regimens that had once been successful.  
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 An article written by Harold C. Neu in 1992 focused on the appearance of 
new strains of infections that had become unresponsive to the antibiotic 
treatments that were in use at that time [60]. At the time of publication, the 
means by which resistance was transmitted was understood as well as the 
specific mechanisms that resulted in loss of function for antibiotics. Given this 
knowledge, the entire article closely explored the increased resistance in specific 
bacterial infections as well as those observed in broader categories such as 
enteric, aerobic, and nosocomial infections [60]. Comparing the alterations that 
have had to be made to treatment strategies over the years is vital to 
understanding the impact of antibiotic resistance.  
  Pneumococcal pneumonia and meningitis are infections commonly 
caused by Streptococcus pneumoniae, a gram positive bacterium also associated 
with infections of the middle ear and sinus cavity [60].  This strain was once easily 
treated through the administration of penicillin, but failed to respond to that 
antibiotic by 1992 [60].  A related bacterium, Streptococcus pyogenes, is 
responsible for a slew of infections, including strep throat and impetigo, which 
were commonly treated with penicillin as well [60]. The use of this specific 
antibiotic treatment throughout the years eventually saw a time when it no 
longer produced the same effects on its target. Unlike S. pneumonia, which 
became entirely resistant to penicillin, S. pyogenes only experienced a decreased 
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response to the antibiotic which was nonetheless detrimental to the success of 
treating infections caused by this bacterium [60]. 
  When exposed to certain settings or antibiotic treatments, some bacteria 
are capable of manufacturing enzymes that counteract antibiotics. Unfortunately, 
this is the case with Enterococcus faecalis, which developed the ability to produce 
penicillinase by 1983 [60].  Penicillinase functions to block the activity of penicillin 
and thus, is a prime example of the bacteria-born enzymes mentioned above. 
Globally, E. faecalis and other closely related species, cause infections associated 
with the abdominal cavity, urinary tract, and endocardium of the heart along 
with other bodily regions [60]. According to Neu, “Enterococci have become the 
third most commonly encountered, hospital-acquired organism in the United 
States” [60]. This was a disappointing discovery considering that hospitals see an 
immense number of patients who may contract an infection caused by these 
now-penicillin-resistant bacteria [60]. 
 Hospitals are not the only setting hindered by the rise in antibiotic 
resistance. Across the globe, and especially in developing countries, diarrheal 
ailments, the result of enteric pathogens, may complicate and take the lives of 
many. Enteric pathogens are bacteria usually introduced into the human 
gastrointestinal tract via tainted food. It would be incredibly damaging to those 
infected if the antibiotics used to counteract the bacteria responsible for these 
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illnesses were to lose their effectiveness. Unfortunately, that is exactly what 
happened; Salmonella, a member of the family Enterobacteriaceae, and its 
relative, Shigella, cause diarrhea and dysentery, respectively, along with other 
serious illnesses [60]. In the case of Salmonella, routine antibiotic treatments 
reached a point where they ceased to affect the infection, drastically reducing 
the number of successful antibiotics [60]. Vibrio cholera, another diarrheal 
disease-causing enteric pathogen infamous as the source of cholera, gradually 
developed antibiotic resistant strains [60]. Certain antibiotics remain capable of 
limiting the dissemination of this disease, but many of the more affordable 
antibiotics, such as tetracycline and sulfonamides, can no longer be used [60]. 
This particular case not only highlights the increase in antibiotic resistance, but 
also emphasizes the indirect consequences that a decrease in antibiotic efficacy 
can produce. Cholera is a disease for which it is crucial to receive treatment, but 
that help may not always be readily available or affordable. Proper care for this 
illness has become increasingly challenging since the more affordable antibiotics 
have lost their effectiveness for this particular bacterium [60].   
 Numerous examples of common infections, their associated bacteria, and 
the state of antibiotic treatments for them are described throughout Neu’s article 
[60]. This is a valuable source for developing an understanding of the large-scale 
effects of antibiotic resistance on the infections that afflict countless individuals. 
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It may not be difficult to admit that the applicability of antibiotics has changed 
over the years, but actually learning about the accumulation of bacterial strains 
involved in antibiotic resistance illuminates the risk it poses. This article 
documented the transition from a time when nearly all infections could be cured 
via penicillin to the year 1992, when a shocking number of those infection 
causing bacteria were no longer thwarted by the tried and true methods. More 
unsettling is the larger message left in the minds of the reader; if this pattern of 
increased resistance continues, will the world see a time when we have 
exhausted antibiotics’ usefulness?  
 Although the previous article thoroughly described the history of 
antibiotics, it did not delve deeply into the mechanisms behind resistance. 
However, this topic is addressed by several additional articles, including one by 
Julian Davies and another by J. L. Martinez and F. Baquero. Additionally, Stuart B. 
Levy suppled useful information for comprehending how antibiotic resistance 
occurs. At the time these works were written, it was understood that bacteria 
multiply via binary fission in which a bacterium is able to replicate itself asexually. 
Since this form of replication requires only one bacterium, there is no 
opportunity for genetic recombination and thus the duplicated version is an 
identical copy of the original. Due to this, if a bacterium has developed antibiotic 
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resistance and carried out binary fission, the new copy would also possess 
antibiotic resistance.  
 A crucial aspect of some bacteria is the presence of plasmids. These 
circular intracellular structures contain extra DNA that is in addition to the 
genetic information stored with the bacteria’s chromosomes. The origin of 
plasmids is thought to have been associated with harsh environmental 
conditions. These challenging conditions were the driving force behind the 
evolution of plasmids because the genetic information and the genes it 
corresponded to were not initially suited to allow survival in these settings [37]. 
However, a bacterium that was capable of surviving in harsh environments most 
likely had certain traits, encoded by genes, which were advantageous to the 
bacterium’s success. Over time, the accumulation of these types of traits led to 
the formation of plasmids. There is not one identical plasmid found throughout 
all bacteria, nor does there have to be only one plasmid per bacterium.  Plasmids 
may not only be unique, there can be a variety of different kinds, allowing for 
multiple advantageous traits in a single bacterium [37]. Plasmids are beneficial to 
bacteria because they may impart antibiotic resistance. This process involves 
existing plasmids merging into larger plasmids while also experiencing losses or 
additions of genes. These modifications often include the movement of genes 
coding for antibiotic resistance which may allow bacteria possessing them to 
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develop resistance [37]. Plasmids that specifically confer antibiotic resistance are 
often referred as “resistant” or “R” plasmids.  Stokes and Hall discovered one way 
in which plasmids are capable of obtaining new genes is through transposons, 
specifically, integrons [76]. These are structural components enabling genes to be 
picked up through a complicated process and eventually incorporated into the 
organism’s genome [14]. This finding was helpful in understanding how plasmids 
may obtain antibiotic resistant genes.  
 It is also commonly known that mutations are the underlying source of 
new genes and novel traits. Likewise, they play a large role in the development of 
antibiotic resistance. It has been determined that the presence of antibiotic 
resistance is dependent on mutations in key genes that are associated with the 
mechanisms antibiotics employ for success. This includes genes that protect 
bacteria from foreign invaders such as antibiotics, as well as genes that play a 
role in accessing, positioning, and synthesizing the antibiotic targets [51]. For 
antibiotic resistance to develop from mutations, more than one gene may need 
to be modified via mutation. In some cases, a mutation in a single, key gene could 
be enough to produce the necessary change, while in others a pathway may 
incorporate multiple genes which may need to accumulate several mutations. 
Current methods for examining types of mutations and mutation rates include 
growing bacterial populations and exposing them to antibiotics in vitro as well as 
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in vivo. Bacteria grown in vitro are usually grown in a petri dish or similar piece of 
laboratory equipment. This allows for reactions between the bacteria and the 
antibiotic to be observed. In comparison, in vivo experiments occur in hosts, 
usually model organisms, and allow researchers to view the effects on entire 
individuals. While both methods can offer valuable data, it is important to 
remember that results of in vitro experiments cannot be assumed to also be the 
same for those in vivo. This point was brought up by Martinez, “These differences 
[in vivo vs. in vitro] highlight the need for very careful interpretation of the results 
obtained with current in vitro models for the emergence of antibiotic-resistant 
mutations in bacterial populations” [51].  This is a crucial point to consider when 
examining the data collected from experiments on antibiotic resistance. It is 
necessary to not only understand how an antibiotic affects a bacterium, but also 
the overall impact it will have on the host.  
 It is important to understand that there is not one universal form of 
antibiotic resistance. What allows one strain of bacteria to be resistant might be 
drastically different than the method employed by a different strain. One such 
mechanism focuses solely on preventing the antibiotic from entering the 
organism. Antibiotics are designed to repurpose a bacterium’s transport 
pathways making those pathways likely targets for resistance [37]. If bacteria can 
block those pathways or somehow render the antibiotic ineffective, then it will 
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decrease the amount of antibiotic that can enter. Since bacteria typically have 
multitudes of transport pathways, completely preventing an antibiotic’s entry is 
difficult. Regardless, this method does hinder antibiotics, a point which was 
noted by Levy, who wrote, “Decreased permeability, however, when 
accompanying other mechanisms of resistance, can provide the host with very 
high levels of resistance that are insurmountable by increased antibiotic dosage” 
[37]. Since there are numerous transport pathways, it is probable that many 
bacteria have not evolved the ability to thwart all antibiotics, thus increasing the 
dosage tends to limit the effects of this form of resistance. However, if this 
method functions in accordance with others, then it could definitely harm the 
antibiotic’s chances for success. [37]. 
 While the method of resistance previously discussed applies to external 
bacterial defenses, there is a larger variety of mechanisms that can operate in the 
bacterium. The simplest strategy is to remove the antibiotic from the bacterium 
before it has had a chance to harm it. Bacteria accomplish this by modifying their 
cellular machinery to export the antibiotic at a faster rate than it can enter the 
cell [37]. If the antibiotic is not able to accumulate, it has fewer opportunities to 
damage the bacterium. At the same time, there are some bacteria that possess 
the ability to prevent antibiotics from ever accomplishing their tasks. In 
successfully blocking antibiotics, some bacteria have developed enzymes that 
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completely protect them from the antibiotic, while others have acquired 
mutations in the specific cellular component the antibiotic targets [37]. The 
targets are often structures necessary for the bacteria to survive, eliminating the 
possibility of simply destroying those components. Instead, a specific mutation 
may allow that portion of the cell to maintain its function while being altered 
enough to inhibit the antibiotic from interacting with it [37].  Along with 
modifying the target structure, some bacteria are capable of producing 
functionally identical components to replace those that have been rendered 
unusable by the antibiotic.  
 A final mechanism of resistance destroys the antibiotic once it is inside the 
bacterium. This method is associated with a topic previously mentioned and is 
demonstrated by the ability of Enterococcus faecalis to produce penicillinase, 
antibiotic-blocking enzyme. Penicillinase is not the sole enzyme responsible for 
blocking antibiotics, but it is a prime example of this mechanism.  The antibiotic 
penetrates the bacterium, but once inside, it will be destroyed or modified by an 
enzyme prior to inflicting any damage.  Several different kinds of this type of 
enzyme have been discovered in bacteria. Each enzyme is unique in the antibiotic 
that it targets as well as its mode of action. The ways an antibiotic is blocked can 
range from destroying the drug altogether to a minute modification that disables 
the antibiotic thus preventing it from reaching its target [37].   
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 Despite the variety of mechanisms employed, bacteria have developed 
novel means to resist antibiotics. As described, some mechanisms are more 
successful than others. Some operate strongly under small amounts of a specific 
antibiotic, but falter at higher dosages, while others remain operational 
regardless of the amount. Nevertheless, all these methods are successful to some 
degree, and are certainly important for understanding the issue of antibiotic 
resistance in general. Much information regarding gene exchange, the way 
bacteria can transfer genetic information, had already been compiled prior to the 
21st century. For example, it was found that some species of bacteria are able to 
produce chemical substances known as pheromones. Typically, the bacterium 
providing the genetic information releases this signal with the purpose of 
attracting another bacterium [37]. Genetic material is then transferred upon their 
contact.  Additional references describe other forms of gene exchange. These 
methods include conjugation, transduction, transposition, and transformation 
and allow bacteria to obtain new genetic information. Collectively, conjugation, 
transduction, and transformation are forms of horizontal gene transfer. This type 
of transfer involves the movement of genes from one bacterium to another by 
means other than reproduction. Although these three methods are all 
categorized as horizontal gene transfer, the mechanism by which genetic 
information is transferred is different in each.  
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 Genetic exchange via conjugation occurs by the movement of plasmids 
from one bacterium to another. Typically, one bacterium contains a plasmid 
while the partner in the exchange does not. The plasmid-containing bacterium 
forms a long, thin, structure made of proteins known as a “sex pilus.” This is a 
relatively complex structure composed of 10-15 specific proteins, produced by 
genes which are thought to only function in the formation of the pilus [14]. The 
structure grows toward the other bacterium, drawing the two closer together 
thus providing a bridge for the plasmid to follow. Prior to the exchange, the first 
bacterium duplicates the plasmid(s) that will be transferred and then allows the 
copy to be sent to the other bacterium via the pilus [14].  Upon receipt of the 
plasmid, both bacteria now possess whatever mutations the plasmid contained 
and are each able to transfer this plasmid numerous times, significantly 
increasing the number of bacteria containing those specific mutations.  This 
explains how a bacterial population can quickly accumulate antibiotic resistance, 
assuming that the exchanged plasmid harbored mutations making resistance 
possible.   
 Initially, the process of conjugation was not well understood and was 
believed to be highly limited compared to the other methods of gene exchange. 
Although conjugation was documented among a variety of cellular organisms, it 
was long believed that it could not occur between gram-positive and gram-
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negative bacteria [14]. The advent of DNA sequencing techniques aided scientists 
in documenting that conjugation was frequently employed in nature, even 
among bacteria [14].  It has also been noted that conjugation is not a species-
specific process, meaning that different species of bacteria may engage in 
conjugation with one another [14].  As the knowledge of this process 
accumulated, it became clear how conjugation contributes to the spread of 
antibiotic resistance.  
 Transduction, unlike conjugation, does not require direct contact between 
bacteria when exchanging genetic information. Rather than transferring a 
plasmid from one source to another via a pilus, transduction makes use of a 
bacteriophage. The vector is a virus specific to bacteria that is capable of storing 
genetic information. Separate from conjugation, which can only share genetic 
information residing in plasmids, bacteriophages may contain information from 
both plasmids and chromosomes.  In order for the information to enter a 
bacterium, the bacteriophage must first arrive at the cells of the bacteria’s host. 
However, the bacteriophage cannot affect just any host cell.  It requires the 
presence of a specific membrane attachment point if it is to infect the host cells 
along with the DNA it is carrying [37].  Upon receipt of the information by the 
host cell, the DNA can follow one of two paths. Both of which release this 
information into the rest of the organism, but vary from one another based on 
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the time needed for this spread to occur. One option is to immediately eliminate 
the host cell by rapid multiplication and release of new bacteriophages through 
the cell’s destruction. The second is to remain in the cell, usually attached to an 
existing chromosome [37]. This option allows both new DNA and preexisting DNA 
to exit the cell at a later time after the bacteriophage has duplicated itself. The 
combination of genetic information can then be transferred to more cells as the 
phage infects them. This movement of genetic material allows for different genes 
to be exchanged. If the bacteriophage contains a mutation that allows antibiotic 
resistance, then that ability can be dispersed throughout numerous cells as the 
phage infects them. 
 The final form of horizontal gene transfer, transformation, does not 
require a plasmid or a bacteriophage to accomplish genetic exchange, nor does it 
need direct contact with another organism.  Instead, genetic information is 
acquired directly from the environment through the cell membrane.  This 
method is challenging to explain because it is difficult to fully characterize the 
extent of the environment from which the bacteria obtains the genetic material 
[14]. By 1994, it was accepted that a large amount of transformation occurred 
among soil microbes and the internal environments of organisms. However, at 
the time, there was only a limited understanding of how genes were transferred 
or how many steps were involved for transformation in such environments [14].  
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Despite this, the importance of transformation was not overlooked by Davies, 
who stated “Transformation of DNA is likely to be an equally significant 
resistance gene transfer process in nature, as most bacterial genera can be 
shown to be competent for transformation under some conditions” [14]. Based 
on this, transformation appears to be a promising source of genetic transfer and 
one for which more understanding is needed.  
 An additional form of genetic exchange is the process of transposition. 
This method takes advantage of small pieces of DNA known as transposons, and 
uses them to pass genetic information to another bacterium. Transposons 
possess the unique ability to move themselves around and insert into various 
places throughout the genome of the organism they reside in. The movement of 
these components is often referred to as “jumping.” Their ability to jump 
increases the survival of the transposons, because it eliminates their dependence 
on a host cell. Unlike a plasmid, which must be successfully inserted into the host 
prior to multiplication, a transposon is capable of merely joining with an already 
established plasmid or preexisting chromosome [37]. Once the transposon has 
imbedded itself in its new location, it can impart its resistance or whatever 
mutations it possesses into the host. Since transposons are not constrained by 
where they can insert, they make reliable vehicles for the transport of resistant 
genes from one bacterium to another [37]. 
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 A considerable amount of information has been collected regarding the 
mechanisms operating to spread resistant genes between bacteria.  It appears 
that a majority of these mechanisms rely on genetic structures to accomplish the 
transmission. There are many differences between these structures, as well as 
their interaction with host cells at the cellular level. Regardless of whether 
bacteria move genetic information by transposition via transposons, 
transformation via bacteriophages, conjugation via plasmids, or transduction 
from the environment, it is apparent that the use of any of these methods could 
allow for the dissemination of antibiotic resistance.  As mentioned for 
conjugation, there is still much to learn of these processes. A greater 
understanding may translate into increased success in preventing resistance.  
 A final commonality among references regarding antibiotic resistance is 
the use of the antibiotics. Most notably is the use of antibiotics in agriculture. 
Khachatourians, explained. “In addition to medical misuse, inappropriate use of 
antibiotics in the agriculture setting is a major contributor to the emergence of 
antibiotic-resistant bacteria” [32]. Using antibiotics in agriculture has gained 
popularity over the years. In 1998, this practice saw a range from 100 to 1000-
fold increase in the antibiotic use in animals compared to use in humans [32].  
Unfortunately, it is not just misuse and increase of antibiotics that is at issue, but 
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even the methods that are in use to dispense necessary antibiotics may have a 
role in the spread of resistance as well.  
 As with humans, plants and others animals are susceptible to microbial 
infections, and similarly, they may be treatable with antibiotics. However, it is not 
always as simple to administer antibiotics to an animal or plant as it is with a 
human, especially if the individual is one of thousands in a herd or planted field. 
In largescale operations, it becomes increasingly difficult to limit dosages of 
antibiotics to a single organism. Due to this, antibiotics aimed at stopping a 
current infection or preventing anticipated ones are often given to entire groups 
of animals or fields of plants [37]. Although the consequences of this may seem 
negligible, it is important to remember that antibiotics often eliminate not only 
the target bacteria, but may also decimate populations of benign, necessary 
bacteria such as those of the human intestinal tract [37].  When multiple 
organisms experience these effects, due to mass exposure to antibiotics, it could 
provide more opportunities for mutations to appear.  
 Although a reasonable amount of the antibiotic use in agriculture is 
appropriately administered for the treatment and / or prevention of infections, 
there still remains a significant number of misapplications. “About 90% of the 
antibiotics used in agriculture are given as growth-promoting and prophylactic 
agents rather than to treat infection” [32]. This suggests that antibiotics could 
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increase both the weight and proportion of profitable meat when incorporated 
into livestock feed. Accompanying this finding was a rise in the amount of 
antibiotics used in agriculture specifically for this purpose.  Larger livestock 
equates to more meat which produces a higher profit for the owner.  With this 
view in mind, incorporating antibiotics into feed became the rule rather than the 
exception.  In 1998, the existing recommended level of antibiotics in feed was 20 
times greater than the maximum amount of 5-10 parts per million recommended 
in the 1950s [32].  This nearly fifty-year period saw a dramatic increase in what 
was deemed an acceptable amount of antibiotics for animals.   
 Despite the fact that antibiotic use within the parameters stated above is 
permissible, it still can have dangerous consequences.  Exposing livestock and 
plants to even minimal levels of antibiotics sets the stage for the selection of 
resistant genes [32].  This is especially harmful if the levels of antibiotics are too 
low to eliminate an infection completely. In this situation, bacteria have been 
exposed to that form of treatment and mutations may have developed. These 
inadequate levels of antibiotics have conditioned the bacteria, and random 
mutations, including those conferring resistance, may increase in frequency in 
bacterial populations.  As of 1992, there was no way to even test for resistant 
mutations among the organisms used by the agricultural industry [37]. The lack of 
a test meant that the allowable maximums for antibiotic use were being 
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increased without any knowledge of the number of resistant bacteria in those 
organisms.  The resistance produced in livestock and crops may not only affect 
the organisms directly exposed, but may could transmit to other animals and 
plants.  The feces from livestock could harbor resistant bacteria while the 
irrigation run off from crops may contain remnants of the antibiotics 
administered [32]. If these sources of antibiotics find their way into surface 
water, they may be spread to other organisms unintentionally. Due to this, 
neighboring farms may be exposed to the same antibiotics and present the same 
strains of resistant bacteria even though only one farm uses antibiotics. The use 
and possible negative results are not limited to specific farms. The fear is that 
antibiotics and strains of resistant bacteria may end up on produce or in meat 
products which then provides a direct pathway into humans thus increasing the 
number of resistant bacteria already present in the general population.  There is 
still much to learn about the impact of a single antibiotic present in agriculture, 
and the importance of this knowledge increases with increasing antibiotic use.   
 A considerable amount of information pertaining to bacteria and antibiotic 
resistance has been collected during the last century. Understanding the 
mechanisms behind resistance is just as important as realizing the impact of 
antibiotics.  Publications that compare the level of resistance and effective 
dosage amounts from the beginning of antibiotic usage, compared to the 
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changes in bacteria observed in the years following, strongly emphasize the 
shifting world of antibiotics and microbes [60]. This initial information has been 
supplemented with the elucidation of the cellular mechanisms behind the 
transmission of resistance. Understanding how mutations in specific genes are 
often targets for the development of antibiotic resistance established a 
foundation for expanding our antibiotic efforts. References also describe the 
forms of genetic exchange available to bacteria along with the strategies 
employed to diminish and eliminate the effects of antibiotics. Finally, the 
expanded use of antibiotics in the agricultural industry illustrates the improper 
use of antibiotics and highlights areas of concern.   Although numerous articles 
written in the same time period are not discussed here, those that have been 
considered seem to be indicative of the level of understanding of antibiotic 
resistance prior to 2000.  Despite the current wealth of information regarding 
antibiotic resistance, there remains room for additional information and 
understanding.  As our understanding of this issue increases, so should our ability 
to respond to and prevent future negative consequences of antibiotic resistance.  
 
III. ANTIBIOTIC RESISTANT INFECTIONS 
There was once a time when people could seek the aid of a physician for a 
simple infection and be confident that their ailment would be cured. The 
unfortunate truth though, is that those simple infections may no longer be easy 
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to cure. Despite the impressive breadth of knowledge and array of antibiotics 
available to doctors, successful treatment may not be possible because those 
infections have become resistant to the antibiotics that were previously used 
against them.  In reality, antibiotic resistant microbes are a worrisome threat in 
today’s world. A handful of bacteria have developed resistance over the years 
contributing to infections that are untouchable by antibiotics. Methicillin-
resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus 
epidermidis (MRSE) are two such examples.  
MRSA 
A gram-positive bacterium, Staphylococcus aureus, was discovered in the 
1880s. Prior to its resistance to antibiotics, this bacterium was known for causing 
infections in post-operative patients as well as small-scale skin infections [16]. 
Until the introduction of penicillin, S. aureus was lethal in 80% of those infections 
[73].  Penicillin provided an effective weapon to use against S. aureus, but 
unfortunately, not one that would be long-lived. Only two years after the 
introduction of penicillin into the healthcare world, S. aureus developed 
resistance to it [16]. To combat this development, methicillin, an antibiotic in the 
same class as penicillin, was introduced. Methicillin was made available in 1959 
and had been in use for only two years when a case of S. aureus methicillin 
resistance was reported from the United Kingdom [16,20]. Reports of a similar 
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nature from across the world followed shortly thereafter. The prevalence of 
MRSA cases are varied across the globe with some countries being more affected 
than others. The United States, Japan, South America, and southern European 
countries typically maintain the highest rates of infection while Switzerland, 
Scandinavia, and The Netherlands have reportedly the lowest rates [17,58,80]. 
MRSA infections are usually nosocomial infections, which are secondary 
infections contracted while in hospitals. Individuals are admitted into the hospital 
to have a surgery or for an infection not related to MRSA and then, while being 
treated for their initial ailment, are exposed to MRSA. Sometimes an open wound 
is not the point of entry for MRSA, but rather it is contact with hospital 
equipment such as a catheter or respirator [29]. Regardless of the source of the 
bacterium, MRSA infections have been increasing in hospitals around the globe 
and, as of the 1990s, have expanded into the general community as well. The two 
primary locations of occurrence have given rise to unique and distinctly named 
infections. The methicillin-resistant strains of S. aureus found in medical settings 
are expectedly termed hospital-associated MRSA (HA-MRSA) while the strains 
residing in communities are community-associated MRSA (CA-MRSA).  Although 
both types of bacteria are resistant to methicillin, they differ on a genetic level.  
The methicillin resistance of the S. aureus bacterium is conferred from the 
gene mecA, which is only found in resistant strains [7,16]. This gene is responsible 
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for the production of PBP2a, a penicillin-binding protein that prevents the 
attachment of beta-lactam antibiotics [7,16,20]. The result of PBP2a is resistance 
to all beta-lactam antibiotics including methicillin. MecA is located in the S. 
aureus chromosome on the staphylococcal cassette chromosome met (SCCmec), 
a mobile genetic element [7,16,20]. As of 2008, seven distinct types of SCCmec 
had been discovered [16]. The types differ from one another by molecular weight 
and can be separated into two groups depending on the resistance they confer. 
Types I, IV, V, VI, and VII are only capable of producing resistance to beta-lactam 
antibiotics while types II and III contain extra genes allowing for resistance to 
multiple antibiotic classes [16].  The varied effects among the SCCmec types 
contribute to some of the differences observed between HA-MRSA and CA-
MRSA. CA-MRSA is resistant to only a small selection of antibiotics and normally 
contains SCCmec types IV and V, whereas HA-MRSA is usually characterized by 
resistance to multiple drugs and harbors SCCmec types I, II, and III [21,34].  
The variation between HA-MRSA and CA-MRSA does not end with the 
differences in SCCmec types, but also includes separate demographics of those at 
risk of an infection as well as unique types of resulting infections. HA-MRSA 
generally causes respiratory, urinary, and bloodstream infections [34]. In 
contrast, CA-MRSA results in mild to severe infections of the skin and soft tissue 
[34]. This includes conditions such as impetigo, cellulitis, and folliculitis as well as 
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abscesses and necrotizing pneumonia [34]. The infections produced from the 
community-associated form of S. aureus comprise a wider assortment of 
infections compared to the hospital-associated strain. This is thought to be due, 
in part, to the presence of supplementary genetic material observed in CA-MRSA. 
In addition to the SCCmec types IV and V, CA-MRSA contains specific virulence 
factors known as Panton-Valentine leucocidin (PVL) [21,34]. The cytokines 
involved in the activation pathway of leukocyte development and tissue necrosis 
are induced by these virulence factors (i.e., properties of pathogenic bacteria that 
facilitate infection) thus directing researchers to associate these genes with the 
types of infections observed in CA-MRSA [34]. 
The demographics of those at risk of MRSA infections also differ. Prior to 
the discovery of individual hospital and community-associated MRSA strains, the 
chances of an individual contracting MRSA was predicted using established risk 
factors. These risk factors include dialysis, recent surgery or hospitalization, 
exposure to catheters and/or other medical equipment, and/or time spent in 
long-term care facilities [34]. If a patient has experienced any of these factors 
they are at a greater risk of contracting a secondary MRSA infection than those 
who do not fall into any of the aforementioned categories.  One study found that 
at least one risk factor was present in 47.5% of healthy community individuals 
with MRSA and 85% in hospitalized MRSA patients [65]. However, these risk 
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factors are not as useful for predicting infections from HA or CA-MRSA. Those 
infected with HA-MRSA are commonly older individuals expressing at least one of 
the risk factors. This is not the case for CA-MRSA which has been seen in younger, 
healthy individuals without previous exposure to any of the risk factors [24,57].  
The earliest reported case of community-associated MRSA came from an 
Aboriginal tribe in Western Australia in 1993 [16]. Since then, CA-MRSA infections 
have continued to increase and have even been documented in healthcare 
facilities. Generally, the countries experiencing higher rates of CA-MRSA are 
those where it is disseminated from communities into hospitals [16]. With CA-
MRSA strains residing in hospitals and other healthcare facilities, there is a 
greater difficulty in discerning whether patients with MRSA have the hospital-
associated or community-associated strain. Identifying the appropriate strain is 
critical for providing the correct treatment considering that both types of MRSA 
have different antibiotic resistances. As noted earlier, HA-MRSA is multidrug 
resistant while CA-MRSA is not. In order to overcome this hurtle, the Centers for 
Disease Control and Prevention established certain criteria to diagnose CA-MRSA 
infections. A patient is diagnosed with the community-associated form of MRSA if 
they present the infection within 48 hours of being admitted to a hospital [16]. 
Additionally, the patient must also have had no exposure to long-term care 
facilities or previous hospitalizations/surgeries within the past year [16]. They 
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cannot have a permanent catheter or had any past MRSA exposure/infection 
[16].  Association with any of the listed experiences could provide an opportunity 
for a HA-MRSA infection and would make it difficult to discern if the infection 
under question was truly from the community-associated strain. Aside from 
these criteria, a genetic analysis of the SCCmec types could also determine the 
form of MRSA.  
Recognizing the differences between HA-MRSA and CA-MRSA is critical in 
treating these infections considering that the underlying genetics of each type of 
microbe may influence how that strain responds to treatment. That being said, 
the first step to treating any MRSA infection is to determine which antibiotics will 
be the most efficacious treatment [7]. To accomplish this, a sample of the 
microbe undergoes susceptibility testing in a laboratory setting where the sample 
is exposed to a range of antibiotics to see which eradicates it. Unfortunately, 
obtaining the results takes time as the bacterium must be cultured and then 
subjected to antibiotics. In most situations, it is not realistic to wait for the results 
before treating the patient. If one were to postpone treatment the infection 
could worsen and could threaten that person’s life if it was not already at that 
stage. Consequently, while awaiting the results of the susceptibility test, doctors 
often prescribe treatments for their patients justifiably based on their prior 
experience and knowledge.  To make the best decision in early treatment, it is 
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important to take into account what portion of the body is infected, the patient’s 
past antibiotic exposure, the local pattern of resistance, and the patient’s health 
[7]. Once the susceptibility test results are complete, the physician can adjust the 
treatment to incorporate the findings.  
Some infections may require more invasive techniques than antibiotic 
doses. Infections may develop to the point that the site of infection needs to be 
cleaned, any fluid build-up needs to be drained, and or surgery is required to 
remove necrotic tissue or foreign bodies. Additionally, healthcare regulations 
require that individuals with certain infections, such as MRSA, follow contact 
precautions while they are in a facility [72]. Contact precautions are devised to 
increase the safety for both infected individuals and those who come in contact 
with them.  Individuals who have been placed under contact precautions during a 
previous healthcare facility visit are often placed under that category 
immediately upon any further visits to that facility, regardless of whether they 
are suffering from an infection [70]. It is likely that this is due to the fact that 
someone with MRSA may serve as a carrier for it later in life, even in the absence 
of symptoms. 
Determining which antibiotics to employ against MRSA may be made more 
difficult by the presence of multidrug resistant strains and variations in resistance 
patterns. Unfortunately, the antibiotic resistance of MRSA varies among strains 
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and geographic regions. As mentioned previously, different countries harbor 
different MRSA infections.  Treatments often vary by infection and location which 
makes it increasingly challenging to develop an overarching treatment strategy. 
Since most of the CA-MRSA strains have not yet developed multidrug resistance, 
they can be treated with a larger variety of antibiotics. Aminoglycosides are often 
used in combination with a beta-lactam to treat skin/soft tissue infections, or 
with a glycopeptide for endocarditis [7]. Again, these treatments are primarily 
employed while awaiting the results of antibiotic susceptibility testing.  HA-MRSA 
infections are often times more challenging to treat because they are usually 
multidrug resistant. In such situations, one of the few remaining treatment 
options is glycopeptides, particularly vancomycin and teicoplanin [7]. A 
treatment’s effectiveness depends on the site of the MRSA infection. If the 
infection is in a difficult spot to penetrate, such as an infection in the central 
nervous system, these antibiotics may be of little use [7]. Additionally, using 
these antibiotics introduces the risk of the bacterium developing resistance to 
them. Since glycopeptides are one of our last lines of defense against HA-MRSA, 
it is critical that they are used appropriately. Patients undergoing glycopeptide 
treatment need to be monitored to ensure they are receiving the proper dosage 
in an effort to eliminate the risk of the infection developing resistance [7]. Also, 
they should only be used when no other antibiotics have been successful.  As 
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with glycopeptides, and for both the safety of the patient and the elimination of 
the infection, antibiotic treatment regimens need to be carefully followed. This is 
primarily due to the fact that S. aureus infections, like MRSA, often result in 
complications during later stages of treatment [25].  
Once an individual has contracted a MRSA infection, regardless of its 
origin, it is crucial to treat it. However, it is more important to prevent these 
infections whenever possible, thus eliminating the need for treatment. First and 
foremost, in an effort to prevent MRSA, all hospitals, clinics, care facilities, etc., 
need to ensure that proper regulations are being followed. There are already 
established measures aimed at preventing the spread of infectious 
contagions/microbes [59]. Of these procedures, frequent handwashing prior to 
and after patient contact is important. Some have even suggested that this step is 
of the utmost importance in preventing the spread of MRSA [66,85].  This may 
seem a fairly obvious measure, one that most individuals have been reminded of 
since childhood. It would probably be difficult to find anyone to argue with the 
benefits of handwashing. Despite the benefit and apparent acceptance of this 
practice, it is often the main regulation that is not fully observed in healthcare 
settings [59,67].  
Additional precautions are more involved than simply washing hands and 
following preset procedures. Research has suggested using decolonization 
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procedures on skin to prevent anyone from carrying the infection topically [47]. 
Carrying strains of MRSA in this manner not only increases the potential of 
transmitting the infection to other individuals, but also places that person at 
greater risk of a relapsing infection. In order to eliminate MRSA colonies, topical 
regimens should be used [86]. However, this form of prevention is not common 
and is often viewed as unnecessary.  As of 2008, topical decolonization 
techniques were not required or suggested by established procedures to 
decrease MRSA infections in the United States [26].  
Given our current understanding about MRSA infections, it is clear that 
there is still much we have to learn. CA-MRSA is still a fairly new type of MRSA 
infection and, as such, there are not many studies focusing on community 
members. Rather, the majority of the studies conducted thus far have focused on 
MRSA infections in hospital settings [34]. Additional community studies have the 
potential to elucidate the means by which CA-MRSA is disseminated and may 
help in developing new strategies to counteract and/or avoid such infections.  
Other improvements can be made in the procedures that are currently employed 
when treating individuals. Hand hygiene requires stricter monitoring and 
increased compliance. Also, contact precautions, mentioned earlier, needs to 
have more clearly defined procedures. Particularly in dealing with when to forego 
patient contact precautions. In the absence of specific guidelines from the CDC, 
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there are inconsistencies as to the length of time an individual should follow 
contact precautions [69]. It would seem that anyone with a previous or current 
MRSA infection should be forced to observe such precautions as a way to ensure 
prevention of exposure to other individuals. Although there is some truth to this, 
forcing a patient to observe these precautions for lengthy periods of time when 
that individual is not currently infected has the potential to negatively impact 
them [12,15,18,28,33,53,56,71,74]. Further improvements focus on expanding 
available treatments through the development of new antibiotics or the 
refinement of existing ones.  
Although, MRSA is a complicated example of an antibiotic resistant 
microbe, it remains only a small aspect of the much larger issue of antibiotic 
resistance. That being said, it does provide a valuable example to illustrate just 
how dangerous and harmful antibiotic resistance can be. MRSA is a complex 
infection, from its multidrug resistant strains, to its presence in both hospitals 
and communities; it is a persistent challenge to treat. As our understanding 
increases, we may find better ways to prevent, diagnose, treat, and even 
eliminate the threat of MRSA. This is a lofty goal, and one that parallels our hope 
for the antibiotic issue as a whole.  
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IV. CAUSES OF ANTIBIOTIC RESISTANCE   
The development of antibiotic resistance is an evolutionary phenomenon 
occurring at the microbial cellular level. As described in the Literature Review, 
antibiotic resistance typically develops when random mutations happen in the 
microbe that hinder or inhibit the efficacy of the antimicrobials being used 
against it.  Although these mutations are specifically responsible for antibiotic 
resistance, additional factors contribute to this process. There is an 
acknowledged association between the use of antibiotics and the prevalence of 
antibiotic resistance [62,82]. As such, a majority of these contributing 
circumstances are associated with how antibiotics are used, both by doctors and 
patients. These circumstances include both the misuse and overuse of antibiotics 
in healthcare and personal settings and the use of antibiotics in livestock and 
agriculture. Indirect causes consist of, but are not limited to, transportation and 
the use of antimicrobial and antibacterial products outside of the healthcare 
industry.  
 
MISUSE AND OVERUSE OF ANTIBIOTICS IN HEALTHCARE SETTINGS  
Misusing antibiotics in a healthcare setting can occur in a variety of ways. 
The misuse or overuse may be the result of certain patients influencing doctor’s 
decisions, lack of readily available or efficient laboratory access, and a desire to 
prevent worsening conditions. It is also important to recognize that healthcare 
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settings are not limited to hospitals, clinics, and private practices, but also include 
residential care facilities, particularly for the elderly. Such facilities are often 
overlooked when considering antibiotic resistance despite the impact they have 
on the healthcare community [78]. 
When people seek the expertise of a doctor, they harbor certain 
expectations; the doctor will provide a diagnosis and will suggest a treatment for 
their ailment, and, in doing so, will provide them with “peace of mind”. 
Unfortunately, because of these expectations, patients may not be satisfied with 
a medical visit if they do not receive the expected diagnosis or anticipated 
prescription. This is especially prevalent with antibiotics [62]. The interaction 
between the doctor and the patient, or patient’s family, may affect the doctor’s 
actions by pressuring them into making prescriptions.  
Complicating this issue is that not everyone in the general public is aware 
that antibiotics are not successful at treating viral infections [46]. In addition, it is 
difficult for patients to determine whether an infection is viral or bacterial 
without the assistance of a physician. Thus, some patients may see a doctor for 
some form of a respiratory tract infection, notoriously caused by a virus, and are 
displeased when they don’t receive antibiotics. They are often under the 
impression that antibiotics are the necessary treatment [46,64]. In an effort to 
obtain those medications, patients have admitted to exaggerating their 
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symptoms to sway the physician’s treatment toward antibiotics [64]. If the 
patient is compelling enough, they may succeed in convincing the doctor that 
antibiotics are the best solution. Unfortunately, this misuse of antibiotics likely 
will not alleviate their symptoms, but will expose both the person as well as the 
environment and those closest to them to an antibiotic. This may provide an 
opportunity to promote resistance.  
Patients are not only able to sway doctor’s judgements by falsely 
representing their symptoms, but also through the relationship they share with 
them. For many physicians, maintaining good relationships with their patients is 
important [62]. Patients need to feel comfortable with their physician and trust 
their judgement. People don’t always understand that a doctor withholds 
antibiotics because it is not appropriate to prescribe them. Due to this, a patient 
may begin to distrust their doctor if they don’t receive certain prescriptions when 
the patient deems it appropriate and will seek another doctor who will satisfy 
their demands. A doctor may be biased by this pressure and feel compelled to 
prescribe antibiotics even when they are not necessary. This situation is common 
in pediatrics [52]. No one enjoys watching a child suffer in discomfort or pain, but 
it is often the influence of parents that can encourage physicians to ignore their 
better judgement. Prescriptions have the ability to make the patient or parent, in 
this case, feel justified for bringing their child to a doctor and are comforted by 
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the thought that progress is being made to treat their child [52]. Regardless of 
the positive effect the dispensing of antibiotics may have, this tactic may be used 
even when antibiotics are useless in treating the patient’s condition [52].  Just as 
with the previous example, this misuse of antibiotics to appease patients allows 
for the possibility of resistance.  
Many people may have intentionally or accidently biased their doctor’s 
diagnosis and prescription due to their actions or information they provide. 
Doctors admit that self-diagnosis, previous healthcare appointments, arguments 
for non-medical circumstances, and direct requests all fall into the category of 
patient pressures that provoke doctors to inappropriately prescribe antibiotics 
[62]. Generally, it is likely that doctors make this decision with the best of 
intentions for the health and satisfaction of their patients. Likewise, people want 
to know that their ailments are being recognized and adequately treated. It 
seems highly unlikely that doctors prescribe and patients request antibiotics with 
malicious intents, but there are the consequences of resistance to consider.  
There are situations in which antibiotics are inappropriately prescribed not 
to merely appease the patient, but in an effort to keep them healthy. During an 
appointment, a patient may present symptoms the doctor would associate with a 
microbial infection, but either s/he does not have the laboratory equipment or 
access to it to confirm the diagnosis. Should the doctor not prescribe antibiotics 
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because s/he can’t validate her/his observations with results? Additionally, if the 
laboratory results do not confirm the presence of a bacterium, does the doctor 
simply accept the findings of the test? If the results are incorrect or not available 
and the doctor forgoes treatment, the patient could get worse. That is not always 
a risk physicians are willing to take. It is not uncommon for a doctor to be 
uncomfortable with diagnostic results fearing an error was made and treat the 
patient simply to be safe [62]. These situations are a gamble; perhaps the 
physician’s instincts and observations are correct and prescribing an antibiotic 
prevents additional health complications. Unfortunately, it is also possible that 
the laboratory results were correct and an antibiotic will be useless.  
The previously described scenario frequently occurs in residential care 
facilities, particularly those for elderly individuals. Over the course of a year, 
approximately 50-70% of all residents in these facilities will receive, at minimum, 
one round of antibiotics [84]. It was also determined that 40% of the given 
antibiotics were not appropriately prescribed for clinical infections [78]. In other 
words, the health condition of the patient did not justify the antibiotics they 
received.  This relatively high percentage of antibiotic misuse would seem to 
encourage negative perceptions of the prescribing doctors, but it is necessary to 
understand the challenging situation eldercare residential facilities pose. Many of 
the residents in need of medical care do not have the cognitive ability to provide 
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accurate medical histories [78]. This prevents doctors from understanding which 
past antibiotics have been prescribed and the patient’s reaction to them. Access 
to samples for cultures and laboratory settings to justify the use of antibiotics are 
not always available either, as mentioned earlier [78]. In addition to these 
existing challenges, one of the aspects that seems most difficult is that a majority 
of the patients in eldercare facilities, because they are elderly, are at risk of 
particularly damaging outcomes if infections are left untreated. Discovering and 
treating infections earlier in elderly individuals could prevent further damage to 
their health [78]. Also, it is valuable to keep in mind that microbial infections in 
older individuals do not always present with the typical symptoms seen in 
younger patients [78]. All of these factors require doctors to base their 
treatments on what they can observe and their medical instincts, taking into 
account the consequences if they do prescribe antibiotics to someone that does 
not need them.  
These situations of misuse and overuse do not necessarily indicate that 
these errors are due to incompetence or lack of concern from doctors. It is 
actually the opposite; physicians are concerned for their patients’ health and 
happiness.  They seem to recognize that maintaining relationships based on trust 
are critical in assisting patients to the best of their abilities and that inappropriate 
prescriptions may help to preserve that relationship and provide “peace of mind” 
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at the expense of the best medical solution. In my opinion, based on the 
situations described above, doctors misuse antibiotics because they fear 
damaging their patients’ health. Despite these best intentions, this misuse and 
overuse of antibiotics could contribute to antibiotic resistance.  
 
MISUSE AND OVERUSE OF ANTIBIOTICS IN PERSONAL SETTINGS  
Inappropriate antibiotic use may not be limited to healthcare facilities nor 
restricted to the actions of physicians. It likely also extends into personal settings, 
as well. Noncompliance and self-medication are two possible sources of 
antibiotic misuse and overuse. The distribution and availability of antibiotics 
could also contribute to their misuse.   
Simply because a physician prescribed a medication with specific 
instructions does not necessarily mean the person receiving the prescription will 
follow those directions. Doctors must give their patients the benefit of the doubt 
when prescribing antibiotics, especially because it is unlikely that self-reporting 
on noncompliance is completely accurate [64]. Noncompliance does not mean 
that the patient isn’t taking any of their prescribed medication, but actually 
consists of any behavior that deviates from following the prescribed dosage and 
directions. This includes failing to complete the entire prescription, altering 
dosage amounts or frequency of doses, and storing leftover antibiotics for later 
use.   
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One study examining patient’s understanding and practices with 
antibiotics found that all antibiotic doses were completed by only three out of 
four patients [64]. This same study also questioned the reasoning behind 
prematurely stopping the prescribed antibiotics and found that a majority 
reported that they felt well enough to not need them [64]. Stopping antibiotic 
use because the symptoms have disappeared seems to be fairly common, but it is 
crucial that entire doses are completed. Not complying with the duration of a 
prescribed antibiotic may result in a reoccurrence of the infection and may 
unknowingly expose others to the microbe. Additionally, some individuals may 
alter their daily dosages so that they receive smaller quantities of the drug than 
prescribed. This action has the potential to promote resistance because the 
microbe is exposed to nonlethal levels of antibiotic [13].  
Self-medicating may also contribute to antibiotic resistance [36]. 
Individuals may treat themselves with antibiotics that are not appropriate for 
their ailment. They may administer an antibiotic for a self-limiting condition or 
one unresponsive to such medications. There is also a risk they will not select the 
correct antibiotic nor administer the correct dosage or duration. There appears to 
be numerous unknowns and risks associated with self-medicating. Unfortunately, 
these actions may expose microbes to incorrect antibiotics or nonlethal doses 
providing an opportunity for resistance to develop.  
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The fact that people self-medicate is not the only concern. What is also 
worrisome is the source of antibiotics. Some individuals will fail to complete their 
prescribed antibiotics, as mentioned, and will save the remaining doses for future 
use [64]. In some countries outside of the United States, people do not need to 
hoard their antibiotics because they are available without prescriptions. One 
study found that antibiotics were available without prescription in the United 
Kingdom, Colombia, France, Morocco, Thailand, Turkey, Spain, Italy, and Belgium 
[64]. It is not that antibiotic sales were legal without a prescription in all these 
countries, just that it was possible to obtain antibiotics under certain 
circumstances [64].  People within the nine previously mentioned countries were 
able to acquire antibiotics from their pharmacist without needing a prescription 
from a doctor [64].  This dispensing of antibiotics not only contributes to 
antibiotic resistance by allowing for inappropriate usage, but also encourages 
self-medicating behavior.  
 
ANTIBIOTIC USE IN LIVESTOCK 
When the phrase “antibiotic resistance” is encountered, it is likely that 
most people immediately think of hospitals, doctors’ offices, and/or people 
suffering from microbial infections. These associations are certainly appropriate, 
but do not complete the entire picture of antibiotic resistance. Antibiotics are not 
solely used in human settings, but are also employed in livestock. It is not 
57 
 
uncommon for animals to receive antimicrobial agents for the prevention, 
treatment, and control of infections [3,50]. Reasons for their use are similar to 
why humans receive antibiotics. Also, the conditions of some farms may be 
enough to warrant the use of antibiotics. Overcrowding and unhygienic 
conditions, especially in aquaculture [50], arguably makes the use of antibiotics 
necessary for the health of the animals.   
However, during the 1950s, the use of antimicrobial agents began in 
livestock (poultry, turkey, swine, and beef cattle) to promote growth and 
contribute to feed efficiency [3,50]. Since livestock are sold as food animals, and 
larger animals fetch higher revenues, it is not difficult to understand why 
antimicrobial agents are used.  However, unlike taking an antibiotic for an 
infection, the use of them in livestock is not necessarily for promoting health. 
Some antimicrobial agents used as growth promoters are given to numerous 
animals in low doses on a continuous basis for lengthy periods of time. These 
conditions are ideal for the selection of resistant bacteria [50]. In the United 
States, as of 2003, 17 classes of antimicrobial agents were considered acceptable 
for the enhancement of growth and feed efficiency [3].  The approval of 
antimicrobial use in livestock does not necessarily mean that there are no 
consequences for this action. In reality, the misuse of antibiotics in agriculture is 
a contributing factor in antibiotic resistance [32,52].  
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There are two main concerns about the use of antimicrobial agents in 
livestock and antibiotic resistance: 1) selection for antibiotic resistant microbes in 
the livestock which may ultimately harm humans, and 2) it unnecessarily exposes 
the environment to antibiotics. As in humans, if livestock are exposed to 
nontherapeutic levels of antibiotics or inappropriate antibiotics for microbial 
infections, it provides a setting for the selection of microbial resistance. This is 
enhanced by the fact that most antimicrobial agents are given to livestock in 
small doses over extended periods of time [50]. An associated concern is whether 
those antibiotic resistant microbes from livestock have the ability to harm 
humans. It is possible that resistant strains of bacteria from animals may be 
antimicrobially resistant in humans if the antimicrobial agents given to livestock 
are the same or similar to those used in humans [3]. Based on this finding, if an 
animal harbors a resistant bacterium it may be possible for that bacterium to find 
its way to humans. Additional evidence was found supporting the existence of 
both resistant bacteria and associated genes in animal products regardless of the 
stage of processing for those products [50]. It may not be surprising that meat 
fresh from the slaughterhouse contains the same bacteria that inhabited the 
organism that had recently been living. However, the idea that those bacteria are 
still present after processing may be worrisome.  
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The products from food animals are not the only source of concern for 
spreading antibiotic resistance. Direct contact with livestock may also serve as a 
route for the dissemination of antibiotic resistance. There is a risk to those who 
work in a close environment with livestock, such as farmers, veterinaries, and/or 
employees of processing facilities. These individuals may contract antibiotic 
resistant infections from infected livestock [50]. If those individuals become 
infected they may pass it to other people with whom they come in contact. Thus, 
the use of antimicrobial agents in livestock may select for resistant microbial 
strains that, through both direct and indirect contact, could harm the human 
population. One study supported the connection between the use of 
antimicrobial agents and resistant bacteria in both livestock and farmers through 
a comparison of a farm that promoted growth via antimicrobial agents versus 
one that did not [50]. Researchers found that both the livestock and the people in 
contact with the animals receiving antimicrobial agents had resistant strains 
among their normal intestinal bacteria while the farm that did not use 
antimicrobial agents did not [50]. This suggests that promoting growth and feed 
efficiency through antimicrobial agents may also promote resistant bacteria that 
are not solely restricted to the livestock.  
The second concern is that the use of antibiotics in livestock will 
unintentionally expose the environment to antibiotics. It has been noted that 
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extended periods of antibiotic use may impact the environment in which the 
antibiotic is being dispensed [44]. Contributing to this issue is the fact that not all 
antibiotics leave the body in an inactive form. Unless a resistant bacterial strain is 
capable of producing enzymes to deactivate an antibiotic, the bacterium may 
simply change the antibiotic target or remove it from the cell. These latter actions 
do not do anything to hinder the activity of the antibiotic. Thus, it is possible that 
active antibiotics enter the environment through the excrement of livestock [44]. 
Once in the environment, those antibiotics, now at nontherapeutic doses, may 
end up in food crops or water supplies where they can select for resistant 
microbes [44,52]. This is a concern not just about the use of antimicrobial agents 
in promoting growth, but also about dispensing antibiotics in animals in general, 
as is seen in the aquaculture industry. Providing antibiotics to aquatic organisms, 
especially fish, can be difficult. To overcome this challenge, the drugs are often 
combined with food which is then placed in the water [50]. Unfortunately, this 
practice exposes entire aquaculture systems to antibiotics and if any of that 
water is released into larger aquatic ecosystems, it could act on pre-existing 
bacterial strains and may select for resistance among those individuals [50].   
Antimicrobial use in the livestock industry is a controversial topic. Animals 
suffering from bacterial infections obviously cannot be left untreated, despite the 
fact that the use of those drugs may impact both the human population and the 
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environment. Similarly, the use of antimicrobial agents as growth promoters may 
seem an unnecessary risk. However, larger food animals, or animals that produce 
more products, are preferred over smaller individuals which contributes to 
greater profits. Regardless of the various motivations for the use of antibiotics in 
livestock, it may contribute to antibiotic resistance among certain microbes.  
 
ANTBIOTIC USE IN AGRICULTURE  
 The use of antibiotics in agriculture and livestock share many 
commonalities. Produce and fruits may come in contact with antibiotics as an 
indirect result of antibiotic use in livestock. As described previously, the 
excrement of animals may contain active antibiotics that could reach agricultural 
products through water run-off or the use of livestock manure as fertilizer.  
However, produce and fruits are also directly exposed to antibiotics, primarily 
through the use of pesticides or in treatment of agricultural diseases. 
StreptomycinTM, GentamicinTM, oxytetracycline, and oxolinic acid are commonly 
used in agricultural settings [75]. In 2002, approximately 45 X 103 kg of antibiotics 
were used as pesticides solely for fruit trees [44]. There is concern that these 
antibiotics, just as with livestock, could have the ability to select for resistance in 
bacterial strains in the surrounding environment. 
 Thus, there is concern that increases in resistance of bacteria observed in 
a clinical setting may result from the impact of agricultural antibiotics on the 
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environment [75]. However, antibiotic residue does not appear to remain active 
for extended periods of time when used in agriculture [75]. This would suggest 
that although the antibiotic might be present in the environment, it is not 
capable of hindering bacteria and wouldn’t provide an opportunity to select for 
resistant microbes. Findings such as the aforementioned, combined with 
regulated practices (the topic of section V), may minimize the fear that antibiotic 
use in agriculture enhances antibiotic resistance.  
 
ADDITIONAL CAUSES   
 Many modes of modern day transportation, ranging from buses to 
airplanes, seem to make the most efficient use of space. The result is that people 
are often crowded together and may come in direct contact with each other. If 
any of those individuals was harboring an infection, for example an antibiotic 
resistant infection, it would not be difficult to transmit it to others given these 
crowded conditions [52]. This form of dissemination is not limited to human 
travel, but is also a factor in livestock transportation as well. Livestock are 
frequently transported in more crowded conditions than are humans. It is 
possible that bacterial strains may spread among livestock in that environment as 
well. Additionally, human patients that are known to be suffering from an illness 
or infection could likely be transported to or from hospitals and care facilities on 
occasion, to receive treatment elsewhere. This movement of infected individuals 
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may increase the number of people they come in contact with, increasing the 
chances for dissemination to others. Although transportation does not directly 
select for the resistance of a bacterial strain as does an antibiotic, it does 
enhance the dissemination of strains that are already resistant. Thus, by 
providing environments conducive to the spread of contagions, transportation 
indirectly contributes to the issue of antibiotic resistance.  
 Another possible cause of antibiotic resistance is the use of antibacterial 
household products. These products’ impact on antibiotic resistance may be less 
easy to document than the impact of transportation. The number of antibacterial 
products has increased from only 23 individual items in 1993 to more than 700 in 
2002 [44]. These products range from common surface disinfectants to 
antibacterial soaps and even plastic products infused with antibacterial 
properties. Regardless of the antibacterial product, the aim is to prevent the 
spread of contagions and hinder the growth of bacteria [41]. In this way, these 
products share similarities with antibiotics, but are not the same in terms of 
modes of action on microbes. However, just as with antibiotic use, there exists 
concern that the use of antibacterial products may influence antibiotic resistance 
in microbes to these products.  
One study found that the increasing use of these products in residential 
settings may impact antibiotic resistance [41]. Antibacterial products commonly 
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contain quaternary ammonium compounds and triclosan [44], the latter of which 
is of concern for antibiotic resistance. There is some debate over whether 
antibacterial products actually promote bacterial resistance to triclosan. 
Generally, antibacterial soaps contain high enough concentrations of triclosan to 
eliminate bacteria, but it was found that the combination of triclosan and soap in 
these products may actually reduce the efficacy of the chemical [41]. 
Additionally, the conditions (temperature, duration of exposure, and 
concentration of chemical) under which triclosan must be exposed to the 
bacterium are rarely achieved with typical hand washing [41].  
In contrast, a separate study examined the effects of using antibacterial 
products, for a one-year period, on antimicrobial resistant organisms residing on 
hands [1]. The findings did not suggest that the use of these products, during the 
allotted time span, had a significant effect on increasing antimicrobial resistance 
[80]. These findings do not necessarily address all concerns about links between 
antibacterial products and increasing antibiotic resistance. As the use of 
antibacterial products increases, the potential for resistance to develop to those 
products may also increase. This is especially possible if the product is capable of 
leaving a residue, as is seen in antibacterial soaps, but not in peroxides or 
alcohols [41]. Soap residues may contain low levels of the antibacterial agents 
which could select for resistant bacteria since these agents may not be potent 
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enough to eradicate any bacterium that encounters them. There appears to be a 
general acceptance in the medical community that extended and heightened use 
of antibacterial products may increase antibiotic resistance among microbes by 
providing an environment in which resistance is promoted [1,41]. Some 
researchers support the use of antibacterial products only for protecting 
recovering patients [41]. Despite this recommendation, antibacterial products 
seem to have become commonplace in the home. 
 Both transportation and antibacterial products may not be the primary or 
most significant causes of antibiotic resistance. This is because their roles as 
contributors to the problem are not always direct nor completely understood. 
Nevertheless, it is important that we attempt to understand their impacts, and 
which areas warrant further investigation. 
 
V. PREVENTING ANTIBIOITC RESISTANCE: CURRENT PRACTICES 
 
 As previously described, antibiotics are used for various treatments in 
numerous settings. Although antimicrobial compounds have improved healthcare 
and saved countless lives, their efficacy is limited by the development of 
antibiotic resistance to them. The existence of antibiotic resistance does not 
mean that antibiotic use is unregulated. Instead, policies exist and practices are 
followed in an effort to provide efficient patient care and prevent further 
antibiotic resistance. These approaches can be grouped into two primary 
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categories; prescribing practices at the physician level and regulations 
surrounding the use of antibiotics in agriculture and for livestock. Additional 
approaches are also employed to diminish or prevent the onset of antibiotic 
resistance.  
 
PHYSICIAN PRESCRIBING PRACTICES  
 
 As previously noted, antibiotic resistance develops, at least in part, to the 
overuse/misuse of antibiotics prescribing physicians. However, some medical 
professionals also maintain practices aimed at limiting the opportunities for 
resistance. In response to antibiotic resistance, physicians in some countries have 
increased their use of clinical tests in determining the proper course of treatment 
[52]. By using more clinical tests, those doctors have a better understanding of 
which microbe plagues their patients and whether that pathogen will respond to 
antibiotics, and if so, which ones. This approach allows doctors to make informed 
decisions when prescribing antibiotics which may decrease the opportunities for 
microbes to be exposed to inappropriate treatments, thereby reducing the 
possibility of developing resistance.  
 Also, in an effort to make the most efficient choices, physicians may rely 
on their medical training and consult prescribing guidelines, decisions trees, or 
follow care paths [52]. Decision trees incorporate choices and associated aspects 
that may include consequences or costs of said choice. In the medical field, 
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decisions trees often contain preferred drug options and recommended 
durations for patient treatment [52]. Where decision trees may be vague or open 
for interpretation, care paths can be more specific. A care path, or clinical 
practice pathway, provides more specific recommendations that follow timelines 
and are evidence-based [52]. Although some may find a care path more 
applicable than a decision tree, the use of either is made in an effort to choose 
the best form of treatment for patients. Either method has the potential to help 
guide a physician to a treatment that may have a reduced risk of developing 
antibiotic resistance.  
 Physicians’ treatment decisions may also be guided by computerized 
antimicrobial approval systems (cAAS) [5]. The Royal Melbourne Hospital, in 
Australia, monitored drug usage and provided prescribing recommendations 
through such a system [5]. This cAAS incited prescribers to critically evaluate their 
medication choices (i.e. the spectrum of the drug used) and treatment durations. 
By encouraging this type of behavior, prescribers may reconsider their treatment 
strategies and promote prescriptions that have a reduced likelihood of promoting 
resistance. A study analyzing the cAAS in the Royal Melbourne hospital found 
that a variety of restricted drugs had a decreased rate of use compared with 
previous year’s data [5]. The overall conclusion was that the computerized 
stewardship system was a successful approach for altering antibiotic 
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consumption in that hospital. It is suggested that such programs could improve 
patient outcomes and lessen the rate of antibiotic resistance [5]. 
 In conjunction with making informed and legitimate treatment choices, 
physicians also attempt to avoid antibiotic resistance through their selection of 
antibiotics. Some doctors will opt to use newer treatments over default 
approaches in an effort to avoid those drugs bacteria may already have an 
increased exposure or resistance to [88]. When certain antibiotics are effective at 
treating bacterial infections, they could easily become the “go-to” drug of choice 
even if other effective drugs exist. Although those antibiotics may be the best 
choice, the frequent use of them leads to increased exposure of bacteria to those 
drugs, which could create an environment encouraging resistance. By using less 
common treatments, doctors can avoid drugs that already have resistance 
developed to them. In addition to using new, less common drug compounds, 
physicians may also attempt to use narrow-spectrum antibiotics whenever 
possible [19,88]. Although broad-spectrum antibiotics may successfully treat 
bacterial infections, it may be at the risk of removing the natural flora of the body 
which in turn could allow additional harmful bacterial to colonize in their place. 
Narrow-spectrum antibiotics are more specific and limited in what they are 
effective against [19] and have a reduced likelihood of creating resistance [88]. 
Doctors may also prescribe multiple drugs rather than a single antibiotic to treat 
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a bacterial infection [52]. Drug combinations could result in synergistic effects 
where the drugs involved become more effective. These practices in selecting 
antibiotics may not always be an option as it depends on the individual and the 
risk those choices pose to their health. However, by making more informed 
choices, doctors have the ability to limit the opportunities for resistance to 
develop. 
 A final approach doctors employ is not specifically in the antibiotics they 
prescribe, but in how they prescribe them. As described previously, the misuse of 
antibiotics results, in part, from patients or relatives of patients expecting 
antibiotics for ailments that are not amenable to these treatments. Not 
prescribing antibiotics when a patient expects them may leave a patient feeling 
dissatisfied with their treatment which could result in loss of trust in their 
physician. This may place doctors in a difficult predicament; do they 
inappropriately treat the patient at the risk of contributing to antibiotic 
resistance in order to maintain the physician-patient relationship, or do they 
prioritize minimizing antibiotic resistance above their patient’s satisfaction? A 
compromise to this predicament is to delay antibiotic prescriptions. If a doctor is 
aware that a patient’s condition will not improve with antibiotics, they may 
advise the patient to wait a certain length of time for their ailment to improve 
[4,52]. If there is no improvement after that time, then the doctor will prescribe 
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the antibiotic. Infections, such as those of the upper respiratory tract that are 
caused by viruses and are thought to need antibiotic treatment, but actually 
don’t, will usually improve [4]. Doctors may also opt to write a patient a 
prescription that cannot be filled until a specific date, a date outside of the time 
frame [4]. Having such a prescription in their possession, rather than a verbal 
agreement, may lead to greater patient satisfaction. This approach is often 
particularly successful when treating children because parents feel that their 
child’s ailment has been acknowledged and efforts have been made to treat it 
[52].  Whether the delayed prescription is suggested verbally or guaranteed 
through writing, this can be an effective approach to limiting the inappropriate 
use of antibiotics.  
 Not all doctors follow these practices nor are all practices the best options 
for every patient. These approaches may vary depending on the situation, the 
resources available, and/or the specific needs of each patient. Despite these 
limitations, the prescribing practices of doctors have the potential to diminish 
antibiotic resistance.  
 
REGULATIONS OF ANTIBIOTICS IN AGRICULTURE/LIVESTOCK 
 
 Monitoring the prescribing practices of physicians is not the only area in 
which attempts are made to curb antibiotic resistance. With the application of 
antibiotics to livestock and agriculture potentially contributing to the 
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development of resistance in bacterial species, there are regulatory practices and 
restrictions to prevent and/or lessen the consequences. Some of these 
approaches attempt to restrict the specific types of antibiotics used, while others 
aim to minimize human exposure. 
 Globally, some countries and health organizations have advocated for the 
complete elimination of the use of any antibiotic compounds for growth 
promotion that are also used in the treatment of humans [3, 6]. The exception to 
this recommendation would be if the use of such drugs were completely 
necessary and unavoidable. Restricting the range of growth promoting antibiotics 
to those that do not have a human analogue could decrease the selection of 
resistance to those antibiotics and maintain their effectiveness in humans. 
Although this could be a beneficial restriction, not all countries comply with this 
suggested course of action [3]. However, some countries in the European Union 
have completely banned the use of growth promoters in food animals, 
horticulture, and aquaculture to prevent the increase of antibiotic resistance [2].  
 Aside from regulating which antibiotics are recommended or legally 
permissible for use in agriculture, there are guidelines to reduce or prevent 
human exposure. These regulations establish that individuals distributing 
antibiotics must wear personal protective gear to prevent direct contact with the 
antibiotics [75]. Additionally, humans have to wait specific periods of time before 
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entering an area that has been treated by antibiotics [75]. Similarly, there are 
certain intervals that must occur between applying antibiotics and harvesting 
crops [75]. These practices aim to prevent humans from encountering any 
lingering antibiotics, thus reducing the likelihood that they would be exposed to 
nontherapeutic levels that could select for resistance in infectious bacteria. 
 In an effort to reduce direct and indirect human contact with antibiotics, 
the conditions that livestock are raised in and how these conditions contribute to 
antibiotic resistance needs to considered.  Use of vaccines, accompanied by 
heightened sanitary conditions in livestock operations, particularly the 
aquaculture industry, reduces the possibility of infections and ailments in the 
animals [6]. Reducing the requirement for antibiotics, in turn, limits the direct 
exposure of antibiotics to animals and the dissemination of those antibiotic 
residues into the environment [6].  
 
ADDITIONAL PREVENTATIVE MEASURES 
 
 Aside from practices in the healthcare, agriculture, and livestock 
industries, there are broad, daily approaches that may prevent the dissemination 
of resistance. Additional efforts include promoting patient education, maintaining 
infection control measures, and encouraging vaccination and proper hygiene. 
Providing multiple sources of information and education can help patients be 
better informed about antibiotic resistance and appropriate antibiotic practices 
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[46].  For example, if patients can understand that their viral infections will not 
improve with antibiotic use, this understanding can diminish the pressure they 
put on their physicians for inappropriate prescriptions. Regulating infection 
control practices, vaccinations, and hygiene practices can prevent the 
transmission of infectious microbes [1,52]. Decreasing the dissemination of 
infectious microbes reduces the morbidity of associated infections resulting in a 
decreased need for, and distribution of, antibiotics. Since a reduction in antibiotic 
use is associated with less resistance, these practices have the potential to 
prevent or decrease antibiotic resistance [46].  
 Whether its physician practice and the guidance they receive, regulations, 
or education of the general public, there are numerous efforts underway to halt 
the increase of antibiotic resistance. Regardless of their success, all efforts must 
be evaluated on a case-by-case basis. Although these efforts are critical in 
reducing the impact and incidence of antibiotic resistance, there remains room 
for improvement.  
 
VI. PREVENTING ANTIBIOTIC RESISTANCE: RECOMMENDATIONS FOR 
FUTURE PRACTICES 
 
 Antibiotic resistance has become a public health concern with no simple or 
immediate solution. Current regulations followed and approaches practiced by 
physicians, the general public, and those in the agricultural/livestock industry are 
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valuable in diminishing the selection of antibiotic resistant microbes. However, 
these methods alone are not enough to prevent our “miracle drugs” from 
becoming ineffective. To sustain a future in which antibiotics can are still 
efficacious, we must maintain our current efforts as well as implement new 
strategies in the following areas: physician education and practices, patient 
education and practices, regulations regarding the use of antibiotics, and drug 
development. 
 
PHYSICIAN EDUCATION  
 
 Within the healthcare industry, the pervasiveness of antibiotic resistance 
is well known. Despite understanding the issue, numerous physicians view 
antibiotic resistance as a concern for secondary healthcare facilities rather than 
their primary practices [82,88]. Some physicians may fail to make the connection 
between their prescribed antibiotics and diminished effectiveness because of 
microbial resistance to the drug. For example, if a patient responds poorly to an 
antibiotic treatment, it is thought to be due to either the presence of a viral 
pathogen or noncompliance with the physician’s instructions [88]. Others harbor 
the belief that those at fault for resistance are the dentists, veterinarians, 
pharmaceutical companies, and pharmacists who inappropriately prescribe 
and/or use antibiotics [52]. Additionally, there are those who maintain the view 
that antibiotic resistance is a significant issue, but do not believe that their 
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actions alone will “fix” the problem [52]. Thus, these physicians do not want to 
risk the health of their patients through limiting their prescriptions since their 
actions will not have a noticeable impact on antibiotic resistance. Although this is 
certainly not the perspective harbored by all physicians, it is likely that there are 
some who maintain these views.  
 If the future of antibiotic resistance is to improve, physicians need to 
abandon the notion that antibiotic resistance is restricted to secondary care. One 
strategy to address this false notion is to provide local resistance data to primary 
care practices [88]. This information would allow physicians to be more up-to-
date in their knowledge of which bacterial infections are currently showing 
resistance in their practice area. This knowledge could alter and improve their 
treatments.  It could also be used to verify resistance as the problem when 
patients don’t respond as anticipated. Both patient health and prescribing 
practices have the potential to improve through the realization that antibiotic 
resistance is capable of being an active agent in primary care, as well as 
secondary care, facilities. 
 It is also crucial to abandon the practice of blaming others for the problem 
[82]. Numerous contributors, ranging from doctors to patients to pharmaceutical 
companies may play a role in encouraging the resistance problem, but no one 
individual is solely responsible. Overcoming the desire to place blame elsewhere 
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will allow more focus on the issue itself. This will encourage all parties to make 
their best efforts to avoid exacerbating the problem further. The view that one 
doctor’s actions will only negligibly alter resistance may be accurate, but if each 
person, whether doctor, patient, or pharmacist, were aware of the issue and 
made every effort not to contribute to it, then the culmination of all those efforts 
could alter the future of antibiotic resistance for the better.   
 
PHYSICIAN PRACTICES  
 
 A physician’s prescribing practices may be influenced by their education, 
their personal experiences or the experiences of their mentors, and/or their 
patients. As previously described, providing more resistance data and 
understanding the role physicians play in antibiotic resistance is crucial to 
changing the course of resistance, but it is not the only physician-related aspect 
that should be changed. There is also room of improvement in the prescribing 
practices of physicians.  
 At the forefront of proper prescribing is the ability to correctly identify 
which microbes are infecting patients. Correct diagnosis does not only stem from 
a medical education, but also from laboratory testing. One study found that the 
availability of laboratory data impacted physician’s knowledge of antibiotic 
resistance [88]. An increased availability and use of point-of-care tests, such as 
the Strep A test or CRP rapid testing, can eliminate diagnostic uncertainty [46,52, 
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62]. If doctors know for certain that a patient’s condition will improve with 
antibiotics, then they can make appropriate prescriptions that will have a 
reduced chance of selecting for resistance in that bacterial species. Many 
facilities already implement laboratory tests such as these, but not all physicians 
have access to the necessary equipment [46]. If the equipment is not in-house, 
then the results could take longer to arrive since they must be outsourced. 
Doctors may feel obligated to opt for prescriptions without the confirmation of 
diagnostic results if there is a chance the patients’ condition may worsen during 
the time it takes to identify the specific microbe. This concern is also associated 
with some diagnostic tests that have lengthy waiting periods before results are 
available. For example, to state that a certain patient’s culture has “no growth” 
takes at least two days using common culturing methods [46]. Waiting two days 
before providing a patient with treatment may be detrimental to their health 
and/or the doctor-patient relationship. Thus, while the increased use of 
diagnostic tests can guide physicians in issuing appropriate prescriptions, an 
improvement in testing techniques may also improve prescribing practices and 
reduce the selection for resistance.  
 Aside from identifying the microbe of interest to ensure appropriate 
treatment, there are additional ways in which physicians can improve their 
practices. Some argue that prescribing fewer antibiotics will decrease the 
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chances of contributing to resistance [88]. If fewer antibiotics are in circulation, 
then fewer bacteria will be exposed to them diminishing selective pressure. It 
may be possible to reduce prescribed antibiotics by promoting practical antibiotic 
practices [46]. In other words, antibiotics should be prescribed only when the 
doctor is certain the patient will receive significant benefit from their use. 
Adopting this approach would mean fewer prescriptions for viral infections. 
Opting for courses of treatment shorter than 10-14days can also reduce microbial 
exposure to antibiotics [44,52]. Some would argue that shorter courses may not 
completely eradicate a bacterial infection, but there have been few studies to 
suggest the benefit of using 10-14 day regimens [52]. Additionally, cycling 
antibiotics, or rotating which ones are frequently used, may prevent further 
resistance development by limiting the exposure of microbes to those drugs [44]. 
Despite the hypothetical benefit associated with the practice of cycling, there is 
little evidence to actually support it [52].  
Implementing one or more of these prescribing practices as a determinant 
in the physicians’ pay may encourage more progressive behavior and encourage 
accurate prescribing practices. This strategy could monetarily reward doctors for 
limited use and accuracy of antibiotic prescriptions [52].  However, this may or 
may not be a successful approach in motivating physicians to curb their antibiotic 
prescribing. The culmination of these efforts, whether it be an increase in 
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diagnostic testing, prescribing fewer antibiotics, and/or providing monetary 
motivation for appropriate prescribing, are ways we can hopefully prevent future 
antibiotic resistance.  
 
PATIENT EDUCATION  
 
 In a world with antibiotic resistant microbes, having well-educated 
patients is paramount. As described in an earlier section, patients can exert 
tremendous pressure on a physician’s prescribing practices. If patients have a 
better understanding of the appropriate uses for antibiotics, they may put less 
pressure on their physicians to inappropriately supply them with those drugs. 
This will not only diminish the misuse and overuse of antibiotics in healthcare 
settings, it could also encourage proper use in personal settings. Promoting these 
practices could eliminate some of the opportunities for resistance.  
 Patient education can occur through many avenues, including 
informational pamphlets, media coverage, K-12 classroom lessons, and 
conversations with medical professionals [32,52,62,64]. Although the issue of 
antibiotic resistance is widely known in the healthcare community, the same may 
not be true for the general public. It is important to ensure that patients are not 
only aware of antibiotic resistance, but that they also understand when 
antibiotics should be used (e.g., for bacterial infections, but not for viral), the 
consequences of misusing antibiotics, and why it is critical to comply with drug 
80 
 
instructions [52,64]. The doctor-patient relationship allows doctors to play a vital 
role in educating their patients [62]. Physicians are not limited to simply 
informing their patients of the dangers of inappropriate antibiotic use; they can 
also help patients feel more comfortable regardless of the recommended course 
of treatment. Physicians can discuss what the patient should expect from their 
treatment, how long symptoms should linger, and when it is appropriate to 
contact the physician again [46]. By ensuring that patients understand and feel 
comfortable with this information, they may have more trust in their doctor’s 
recommended treatments even if those regimens do not include prescriptions for 
antibiotics. Educating and conversing with patients could be one way to reduce 
the misuse of antibiotics, potentially without sacrificing the satisfaction and trust 
of the patient.  
Many doctors are limited to only a few minutes of consultation with their 
patients. This time allotment makes it difficult to adequately explain their 
prescription choices and to discuss any concerns with their patients [62]. One 
way to overcome this difficulty is to combine a physician’s verbal advice with 
printed material [62]. This approach provides the physician with time to explain 
their concerns while giving the patient additional information they can consult at 
a later time.  
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Educating patients via one of these methods alone may not reverse the 
misunderstanding that antibiotics are appropriate for all ailments [46]. Instead, 
providing multiple sources of information through various means may help 
patients become well-informed and increase the appropriate use of antibiotics. It 
is also important to implement educational methods that are tailored to specific 
regions [62]. Just as doctors have argued that having local resistance data would 
be helpful, so too would be patient education that addressed the specific 
concerns for the areas in which the patients reside [62]. Antibiotics and the 
associated concerns for their use are perceived differently depending on the 
cultural lens they are viewed through. Thus, an educational approach that might 
be successful in one country may not engage the target audience of another. 
Through a multi-pronged, country-specific approach, patients can become more 
educated about antibiotics, the issue of resistance, and the role they play.  
 
PATIENT PRACTICES 
 
 There are multiple ways in which the practices of patients and the general 
public can diminish, or at least not increase, antibiotic resistance. Complying with 
treatment directions will ensure that bacterial infections are treated with 
therapeutic levels and for long enough durations to eliminate infections. Not 
adhering to those guidelines may destroy only a portion of the bacterial 
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population, while leaving the remaining members alive and exposed to that 
antibiotic. This creates situations ideal for selecting for resistance.  
Another obvious and crucial strategy, at both the patient and physician 
levels, is to prevent the transmission of resistant strains. An excellent way to 
pursue this approach is through proper hand hygiene [32,61]. Although 
developed nations maintain and promote such practices, developing nations may 
not have the resources or programs to prevent infections that spread this way 
[61]. Also, taking advantage of vaccinations and making vaccinations globally 
available could contribute to reducing antibiotic resistance among microbes [52]. 
If all humans adopted these practices, antibiotic resistance could be reduced and 
possibly prevented.  
 
ANTIBIOTIC GUIDELINES  
As previously explained, strategies focusing on the education and 
antibiotic habits of patients and physicians appear to be valuable in reducing the 
presence of antibiotic resistance. Nevertheless, additional antibiotic regulations 
could also be beneficial. Specifically, improvement in drug guidelines will help to 
maintain the efficacy of current antibiotics and diminish their misuse [52,62].  
 Some studies have suggested a connection between inappropriate 
prescribing practices and poorly constructed antibiotic guidelines [52,62]. 
Guidelines exist to advise prescribers in their treatment choices. Although a 
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physician’s judgement may be positively influenced by guidelines, often the 
guidelines can only provide suggestions, leaving the ultimate decision up to the 
physician [52]. In this way, the consequent actions of a physician may not have 
been affected by the guidelines whatsoever. Some guidelines are too focused on 
selecting the correct drug and neglect to provide information suggesting shorter 
durations or the option to withhold treatment altogether [52]. Selecting the 
appropriate drugs are indispensable in providing proper treatment, however, as 
previously described, not all situations may call for antibiotics. Guidelines that 
present the drug choice as the primary concern over the decision to treat may 
mislead prescribers. Additionally, pharmaceutical companies may frequently 
promote specific guidelines if one of their products are included in them [52]. The 
support of a pharmaceutical company may create the appearance that their drug 
is the premier option, thus encouraging physicians to employ that drug over 
others that are equally effective.  
 Based on these drawbacks, the creation of new guidelines could 
encourage more progressive prescribing. Guidelines could include pathways (e.g., 
decision trees) to help physicians decide if antibiotic treatment for a patient is 
appropriate and, if so, suggestions for limited durations to avoid prolonged 
exposure. Some studies also suggest that guidelines should be created by 
multiple medical disciplines to encourage better communication and cooperation 
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between the various fields and prescribers [62]. Adopting a more communicative 
relationship between different disciplines would not only promote a more 
expansive understanding of antibiotic resistance, but would also encourage more 
appropriate prescribing practices [62].  
 
DRUG DEVELOPMENT 
 Microbial antibiotic resistance is particularly worrisome because of its 
ability to render our drugs useless. This unfortunate consequence means, if left 
unchecked, resistance could become increasingly prevalent. Perhaps we will see 
a day when we still have a wide choice of antibiotics, but their affect is negligible 
and bacterial infections that were once easy to effectively treat would become 
life threatening. The discovery and development of new antibiotic compounds 
will not solve the problem of resistance, but will provide new drugs to combat 
those bacterial species that are unaffected by commonly employed methods. 
Thus, supporting and encouraging drug development is a potential avenue for 
countering antibiotic resistance [38]. Unfortunately, not only has the discovery of 
new antibiotics lulled, but few companies are actively searching [4,8,45].  
 Few argue that new drugs would not provide new treatments to replace 
those which are faltering [38]. However, despite the benefits of drug discovery, 
few new compounds have ever reached market. Between 1962 and 2012, only 
one new antibiotic was marketed for clinical use [45]. Exacerbating this situation 
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is the reduction in the number of pharmaceutical companies that are actively 
pursuing new antibiotics. The combination of minimal success, economic 
environment, and regulatory barriers has greatly hindered the willingness of 
companies to continue to investigate new antibiotics [4,45]. Some 
pharmaceutical companies have opted to continue the search, but at a 
diminished capacity, while others, such as 18 of the larger companies, have 
completely withdrawn from the antibiotic hunt [4,45]. Refocusing efforts on 
antibiotic discovery may not be as easy as simply encouraging pharmaceutical 
companies to return to those activities. Multiple processes and organizations are 
involved in the path from discovery to clinical use. For new drugs to be 
developed, policies, funding, regulations, and timelines may have to be altered at 
the level of both companies and governments [36]. 
 Cultivating and supporting the desire to develop new antibiotics again 
could impact the issue of resistance, not by halting its progression entirely, but by 
providing more options for treatment. Simply revitalizing the search for new 
antibiotics does not guarantee the discovery of more antibiotics. In response, 
some argue that only encouraging the practiced approaches to drug discovery 
will not be fruitful [8,45]. Instead, others recommend companies reemploy older 
methods that, when coupled with today’s technology and understanding, could 
be highly synergistic [45]. These suggestions include returning our focus to soil 
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bacteria, developing more prodrugs (drugs that are administered in an inactive 
form and are cleaved into activation), or designing drugs that target the 
mechanisms of resistance [38,45]. Although these may be worthwhile 
approaches, discovering new antibiotics will not solve the issue of antibiotic 
resistance, it will only delay the progression of resistance among pathogenic 
bacteria.  
 Numerous strategies have been described and it is highly likely that more 
exist. These approaches vary in their focus and approach, but they have the 
potential to slow or prevent future occurrences of antibiotic resistance. 
Regardless of the method, the critical point is that individually, any one of these 
strategies may not have an impact on the resistance issue. Instead, it is the 
synergistic combination of these strategies that may alter the path of resistance. 
Employing a multi-faceted approach, in which patient/physician education is 
accompanied by guideline revision, drug discovery, and multiple other efforts, 
may be the only way to control antibiotic resistance [52]. As such, if we are to 
alter antibiotic resistance, it will likely come through multi-scale efforts employed 
on multiple fronts.  
 
VII. CONCLUSION  
 In 1946, following the widespread use of penicillin, Alexander Fleming 
voiced his concerns that there would one day be a public abuse of this “miracle 
87 
 
drug” [4]. In the same statement, he also expressed his apprehension that such 
an abuse would certainly have ramifications. The inappropriate use of penicillin 
would not only affect the misusing individual, but would promote a resistance to 
that drug that could claim the lives of countless others [4]. Unfortunately, his 
concern was not unfounded, and the ideas behind it were not solely limited to 
penicillin.  
 While antibiotic discovery and synthesis was plentiful, it may have been 
difficult to imagine a future in which humans did not reign over the top of the 
microbial food chain. Antibiotics provided an amazing opportunity to overcome 
bacterial infections that previously could decimate populations. So much so, that 
people were confident the human race would see a day when bacterial infections 
were eradicated [36]. Although the discovery of antibiotics may have initially 
supported this ideal outlook, it has not been the result. The initial and continued 
use of antibiotics promotes natural selection of random mutations that allow for 
the development of resistance [52]. As both new and old antibiotics continue to 
be used and abused, resistance will persist. The issue of bacterial resistance to 
antibiotics has become a global concern [38]. A slew of common infections, once 
easily treated with antibiotic regimens, now have little to no response to drugs. 
Staphylococcus aureus is a prime example of such an infection. There was a time 
when antibiotics were effective against this bacterium, but now methicillin-
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resistance S. aureus (MRSA) is prevalent in both community and in healthcare 
facilities. Although S. aureus is specifically resistant to methicillin, it serves as 
proof that microbial infections are able to claim lives despite the existence and 
availability of antibiotics. This is possible because microbes, such as this specific 
bacterium, have developed resistance.  
 There is no one individual or occupational field solely at fault for the 
existence of antibiotic resistance. Physicians may contribute to the problem by 
prescribing antibiotics for self-limiting infections or for other situations in which 
an antibiotic isn’t beneficial or appropriate. Although it may be easy to limit the 
misuse of antibiotics to the healthcare industry because of a physician’s access to 
antibiotics and their ability to prescribe them, to do so would overlook additional 
areas of concern. Resistance can be encouraged by patients’ noncompliance, the 
illegal and nonprescription use of antibiotics, or even pharmaceutical companies 
that promote the use of one antibiotic over other equally efficacious options. The 
use of antibiotics in the agriculture and livestock industries may provide an 
opportunity for nontherapeutic levels of antibiotics to enter the environment, 
creating situations ideal for selecting for resistance. The increasing abundance of 
household products advertising antimicrobial benefits may also affect resistance 
in the same manner. Additionally, unhygienic conditions and failure to vaccinate 
set the stage for the development and dissemination of resistant strains. The 
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culmination of these factors, rather than any one in particular, promote and 
sustain antibiotic resistance.  
 Efforts are actively underway to prevent future antibiotic resistance and to 
promote the sustainable use of antibiotics. Physicians try to minimize their use of 
these drugs and educate themselves about regional resistant infections. 
Attempts are being made to help the general public understand the issue of 
resistance and when antibiotic use is appropriate. In conjunction with additional 
methods and approaches, these efforts are an attempt to create a more 
knowledgeable population that uses antibiotics in an appropriate manner.  
Although these practices are valuable in preventing antibiotic resistance 
from worsening, there remains room for improvement. Current practices should 
by no means be discontinued or discouraged, but new approaches should also be 
implemented. This includes, but is not limited to, reviving investment in antibiotic 
discovery and development, increasing the availability of diagnostic testing, and 
establishing guidelines for strict regulation of antibiotic use. Maintaining current 
practices and working toward future improvements may not only prevent 
antibiotic resistance from worsening, but may diminish it as well.  
Regardless of current and even future efforts, it seems that antibiotic 
resistance may never be completely eliminated. Antibiotics are critical for saving 
lives and their application, even when used appropriately and responsibly, has 
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the potential to promote resistant microbes [36]. It is not practical or moral to 
sacrifice the health of patients for the sake of completely eradicating resistance. 
Considering that fact, along with the existence of organisms that harbor intrinsic 
mechanisms for resistance, it would be highly unlikely that the human population 
will ever experience a time when there is not a single drug resistant microbe [36]. 
However, that does not imply that the current state of antibiotic resistance 
cannot be improved. If action isn’t taken, antibiotic resistance could potentially 
expand until all antibiotics are rendered useless. Under those conditions, it is 
possible that countless individuals could succumb to common infections that 
were once easily treated with antibiotics. However, encouraging and maintaining 
appropriate antibiotic use through multiple approaches and across numerous 
disciplines could improve the state of antibiotic resistance.  
To keep our “miracle drugs” effective, numerous changes will have to be 
made. The tendency to blame others must be abandoned, as must the notion 
that an individual’s actions won’t affect the situation. It is time to stop pointing 
fingers, and instead, focus on making positive contributions in the fight against 
resistance. It is also crucial to recognize that only targeting one group or making 
one change will not produce desirable results. To combat antibiotic resistance, it 
will require a broad, multifaceted, approach that targets practices, education, 
and regulations at multiple levels ranging from the general public to the 
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government [52]. One person alone did not cause resistance, nor will a single 
individual be able to change it, but there is certainly the potential for each one of 
us to be affected by it. Thus, everyone has a part to play and it begins by 
understanding antibiotic resistance.  
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